

Where Medicine and Science Meet**Table of Contents:**

Subject	Page(s)
Patents	2
Book Chapters	3-4
Publications	3-38
• Quantitative Immunofluorescence	4-6
• Flow Cytometry	6-8
• Lymphocyte Subsets	8-9
• Antigenic Analysis of Normal Bone Marrow	9-11
• Leukemia	10-32
- T-cell LGL Leukemia	11
- ALL	11-12
- MDS	12-16
- AML	16-26
- MPAL	27
- AML RAM	27
- AML-Downs Syndrome	27-28
- AML- Gemtuzumab Ozogamicin (Mylotarg™) treatment	28-31
- CLL	31
- CML	31-32
- MPL-	32
• Plasma Cell	32-33
• BMT	33-34
• Lymphoma	34
• Cytogenetics, FISH, SNP/CGH	34-35
• Combining Flow Cytometry and Molecular Biology	35
• Molecular Genetics	35-36
• Basic Research	36-39

Patents

1. Wardlaw SC, Levine RA, Rodriquez RR, Loken MR: Method of improving the demarcation and separation of cells in centrifuged blood samples. US Patent #4,695,553.
2. Recktenwald. DJ, Kerndt RS, Chen CH, Loken MR: Method and materials for calibrating flow cytometers and other analysis instruments. US Patent #4,704,891.
3. Evans EL, Gonchoroff NJ, Griep PR, Houck DW, Katzmann JA, Kyle RA, Loken MR: Detection of cellular DNA. US Patent #4,885,237
4. Loken MR, Terstappen LWMM: Method for discrimination between intact and damaged cells in a sample. US Patent #5,057,413
5. Loken MR, Terstappen LWMM: Method for analysis of cellular components in a fluid. US Patent #5,047,321
6. Loken, M.R. Civin C.I., Shah V. O.: Method to determine the composition of bone marrow samples. US Patent # 5,137,809
7. Mickaels RA, Dost RK, Terstappen LWMM, Loken MR: Method for data transformation. US Patent #5,224,058
8. Loken, MR, Parks, DR, Hardy RR: Method and apparatus for distinguishing multiple subpopulations of cells in a sample. European Patent 0121262B1
9. Terstappen, LWMM, Loken MR, Huang, S, Olweus, J, Lund-Johansen, F: Phenotypic characterization of the hematopoietic stem cell. US Patent #5,840,580
10. Loken, MR Method for collecting purified cells US Patent # 7,045,295
11. Loken; Michael R. Joshi; Sanjaya N. System, method, and article for detecting abnormal cells using multi-dimensional analysis US Patent # 8,630,833
12. Loken; Michael R. Joshi; Sanjaya N. System, method, and article for detecting abnormal cells using multi-dimensional analysis European Patent # 1859377
13. Michael R. Loken, Andrew P. Voigt, SYSTEM, METHOD, AND ARTICLE FOR DETECTING ABNORMAL CELLS USING MULTIDIMENSIONAL ANALYSIS, U.S. Patent # 11,639,936
14. Michael R. Loken, Andrew P. Voigt, SYSTEM, METHOD, AND ARTICLE FOR DETECTING ABNORMAL CELLS USING MULTIDIMENSIONAL ANALYSIS, CN. Patent # 110023759
15. Michael R. Loken Andrew P. Voigt: SYSTEM, METHOD, AND ARTICLE FOR DETECTING ABNORMAL CELLS USING MULTI-DIMENSIONAL ANALYS U.S. Patent Application No. 18/186,747

Book Chapters

Zehentner, B.K. (2019). Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies. In: Druley, T. (eds) Minimal Residual Disease Testing. Springer, Cham. https://doi.org/10.1007/978-3-319-94827-0_3.

Loken, M.R., Brodersen, L.E., Wells, D.A. (2019). Monitoring AML Response Using “Difference from Normal” Flow Cytometry. In: Druley, T. (eds) Minimal Residual Disease Testing. Springer, Cham. https://doi.org/10.1007/978-3-319-94827-0_4.

Loken MR. The mechanics of quantized hematopoiesis. In: Emandi A, Karp JE, editors. Acute leukemia: an illustrated guide to diagnosis and treatment. New York: New York Demos Medical; 2018. p. 239–54.

Loken MR. Quantized Hematopoiesis. In: Emandi A, Karp JE, editors. Acute leukemia. New York: Demosmedical; 2018. P. 243.

Loken M. Residual Disease Detection. New York, NY: Springer Publishing Company; 2018.

Todd E. Druley, **Barbara Zehentner**. Minimal Residual Disease Testing Current Innovations and Future Directions. Chapter 3: Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies.

Todd E. Druley, **Michael R. Loken, Lisa Eidenschink Brodersen and Denise A. Wells**. Minimal Residual Disease Testing Current Innovations and Future Directions. Chapter 4: Monitoring AML using “Difference from Normal” Flow Cytometry.

Lisa Eidenschink Brodersen, Barbara Zehentner, Luise Hartmann, Keely Ghirardelli, Michael R Loken, Denise A Wells, Flow Cytometry and SNP/CGH Array can Definitively Identify Myelodysplastic Syndrome in Patients with Unexplained Cytopenias, 12th International Symposium on Myelodysplastic Syndromes, 5/1/2013.

Wells DA, Loken MR, Myelodysplastic Syndromes: Pathobiology and Clinical Management, Chapter: Diagnostic and Prognostic Utility of Flow Cytometry in MDS Page 247 - 266, Editors: Steensma. Informa Healthcare USA, Inc., New York, NY Edition 2nd ,2009.

Wells DA, Loken MR. Diagnostic and Prognostic Utility of Flow Cytometry in MDS, in Myelodysplastic Syndromes, Pathobiology and Clinical Management, 2nd Edition, David P Steensma ed. Informa, New York, pp247-266, 2008.

Steensma: Myelodysplastic Syndromes: Pathobiology and Clinical Management, 2nd Edition
December 30, 2007, Diagnostic and Prognostic Utility of Flow Cytometry in MDS. **Denise A. Wells and Michael R. Loken.**

Loken MR. Multidimensional data analysis in immunophenotyping. *Curr Protoc Cytom* 2001 May; Chapter 10: Unit 10.

Loken MR, Green C, Wells DA: Immunofluorescence of cell surface markers. in Flow Cytometry- A Practical Approach. 3rd ed. M. Omerod ed. Oxford Univ. Press, Oxford, 2000, pp 61-82.

Loken MR, Wells DA, Clinical Flow Cytometry, Chapter: Normal antigen expression in hematopoiesis: Basis for interpreting leukemia phenotypes, Editors: Stewart CC and Nickolson J. Wiley-Liss, Inc.2000.

Loken MR, Wells DA: Normal antigen expression in hematopoiesis: Basis for interpreting leukemia phenotypes. In "Immunophenotyping", Stewart C, Nicholson J. Eds. Wiley Liss, Inc. New York, 2000, pp133-160.

Owens MA, **Loken MR.** Flow Cytometry Principles for Clinical Laboratory Practice: Quality Assurance for Quantitative Immunophenotyping. New York, NY: WileyLiss; 1995.

Loken MR, Wells DA: Immunofluorescence of cell surface markers. in Flow Cytometry- A Practical Approach. 2nd ed. M. Omerod ed. Oxford Univ. Press, Oxford, 1994, pp 67-91.

Loken MR, Shah VO, Terstappen LWMM. In: Knapp W, editor. Multicolor analysis of myeloid antigens on normal human bone marrow. Oxford University Press; 1989. p. 859-62. 728.

Terstappen L, Shah V, Civin C, Hurwitz C, **Loken M.** Multidimensional flow cytometry as a new approach for discrimination between normal and leukemic cells in peripheral blood and bone marrow. In: Jansen A, ed. Progress in Cytometry II: Flow and Image. Erembodegen, Belgium: Becton-Dickinson; 1989:4-29.

Horan PK, **Loken MR:** A practical guide for the use of flow systems in flow cytometry. In MA Van Dilla, ed. Instrumentation and Data Analysis. San Diego. Academic Press, 1985 pp. 260-280.

Loken MR: Cell surface antigen and morphological characterization of leukocyte populations by flow cytometry. Methods in Hematology, Vol 13. P. Beverly, ed. (1985) pp 132-144.

Loken MR, Stout RD, Herzenberg LA: Lymphoid cell analysis and sorting. In: "Flow Cytometry and Sorting". Melamed MR, Mullaney PF, Mendelsohn ML, eds. John Wiley and Sons, New York, pp 505- 528, 1979.

Publications

Quantitative Immunofluorescence

Voigt AP, Eidenschink Brodersen L, Pardo L, Meshinchi S, Loken MR. Consistent quantitative gene product expression: #1. Automated identification of regenerating bone marrow cell populations using support vector machines. Cytometry A. 2016 Nov;89(11):978-986. doi: 10.1002/cyto.a.22905. Epub 2016 Jul 14. PMID: 27416291; PMCID: PMC5132084.

Loken MR, Voigt AP, Eidenschink Brodersen L, Fritschle W, Menssen AJ, Meshinchi S, Wells DA. Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals. Cytometry A. 2016 Nov;89(11):987-996. doi: 10.1002/cyto.a.22999. Epub 2016 Oct 18. PMID: 27754578; PMCID: PMC5132067.

Loken MR, Voigt AP, Eidenschink Brodersen L, Fritschle W, Menssen AJ, Wells DA. Consistent quantitative gene product expression: #3. Invariance with age. Cytometry A. 2016 Nov;89(11):997-1000. doi: 10.1002/cyto.a.22997. Epub 2016 Oct 18. PMID: 27754615; PMCID: PMC5132053.

Eidenschink L, DiZerega G, Rodgers K, Bartlett M, Wells DA, Loken MR. Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 18 months. Cytometry B Clin Cytom. 2012 Jan;82(1):18-25. doi: 10.1002/cyto.b.20611. Epub 2011 Aug 2. PMID: 21812106.

A Wells D, Loken MR. Flow cytometric mean fluorescence intensity: the biophysics behind the number. Leuk Res. 2008 Jun;32(6):845-6. doi: 10.1016/j.leukres.2007.10.002. Epub 2007 Nov 19. Erratum in: Leuk Res. 2008 Nov;32(11):1792. PMID: 18023867.

Stelzer GT, Shults KE, **Loken MR**. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci. 1993 Mar 20;677:265-80. doi: 10.1111/j.1749-6632.1993.tb38783.x. PMID: 8494214.

Sheckler VL, **Loken MR**. Routine quantitation of white cells as low as 0.001 per microL in platelet components. Transfusion. 1993 Mar;33(3):256-61. doi: 10.1046/j.1537-2995.1993.33393174453.x. PMID: 7679804.

Loken MR, Civin CI (1993) Laboratory assessment of lymphohematopoietic progenitor and stem cells. In: Smith DM, Sacher RA (eds) Peripheral blood stem cells. American Association of Blood Banks, Bethesda, MD, pp 19–31

Terstappen LW, Huang S, Safford M, Lansdorp PM, **Loken MR**. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood. 1991 Mar 15;77(6):1218-27. PMID: 1705833.

Terstappen LW, Safford M, **Loken MR**. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia. 1990 Sep;4(9):657-63. PMID: 2395385.

Terstappen LW, **Loken MR**. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol. 1990 Jul;2(4):229-40. PMID: 1703434.

Terstappen LW, Shah VO, Conrad MP, Recktenwald D, **Loken MR**. Discriminating between damaged and intact cells in fixed flow cytometric samples. Cytometry. 1988 Sep;9(5):477-84. doi: 10.1002/cyto.990090512. PMID: 2

Loken MR, Shah VO, Hollander Z, Civin CI. Flow cytometric analysis of normal B lymphoid development. Pathol Immunopathol Res. 1988;7(5):357-70. doi: 10.1159/000157129. PMID: 3266012. 460298.

Shah VO, Civin CI, **Loken MR**. Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis. J Immunol. 1988 Mar 15;140(6):1861-7. PMID: 2964486.

Loken MR, Civin CI, Bigbee WL, Langlois RG, Jensen RH. Coordinate glycosylation and cell surface expression of glycophorin A during normal human erythropoiesis. Blood. 1987 Dec;70(6):1959-61. PMID: 2445402.

Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood. 1987 Nov;70(5):1316-24. PMID: 3117132.

Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood. 1987 Jan;69(1):255-63. PMID: 2947644.

Civin CI, Banquerigo ML, Strauss LC, **Loken MR**. Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10-positive progenitor cells in normal human bone marrow. Exp Hematol. 1987 Jan;15(1):10-7. PMID: 3096755.

Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH, **Loken MR**, Civin CI. Antigenic analysis of hematopoiesis. IV. The My-11 hematopoietic cell surface antigen is expressed by myelomonocytic and lymphoid, but not erythroid, progenitor cells. Exp Hematol. 1986 Nov;14(10):935-45. PMID: 3464448.

Loken MR, Lanier LL. Three-color immunofluorescence analysis of Leu antigens on human peripheral blood using two lasers on a fluorescence-activated cell sorter. Cytometry. 1984 Mar;5(2):151-8. doi: 10.1002/cyto.990050209. PMID: 6370629.

Ryffel B, Willard-Gallo KE, Tammi K, **Loken MR**. Quantitative fluorescence analysis of cyclosporine binding to human leukocytes. Transplantation. 1984 Mar;37(3):276-80. doi: 10.1097/00007890-198403000-00012. PMID: 6367167.

Loken MR, Stall AM. Flow cytometry as an analytical and preparative tool in immunology. J Immunol Methods. 1982;50(3):R85-112. doi: 10.1016/0022-1759(82)90161-2. PMID: 7047643.

Taupier MA, Kearney JF, Leibson PJ, **Loken MR**, Schreiber H. Nonrandom escape of tumor cells from immune lysis due to intraclonal fluctuations in antigen expression. Cancer Res. 1983 Sep;43(9):4050-6. PMID: 6871846.

Loken MR, Houck DW. Light scattered at two wavelengths can discriminate viable lymphoid cell populations on a fluorescence-activated cell sorter. J Histochem Cytochem. 1981 May;29(5):609-15. doi: 10.1177/29.5.7252128. PMID: 7252128.

Loken MR. Simultaneous quantitation of Hoechst 33342 and immunofluorescence on viable cells using a fluorescence activated cell sorter. Cytometry. 1980 Sep;1(2):136-42. doi: 10.1002/cyto.990010208. PMID: 7028425.

Loken MR, Parks DR, Herzenberg LA. Two-color immunofluorescence using a fluorescence-activated cell sorter. J Histochem Cytochem. 1977 Jul;25(7):899-907. doi: 10.1177/25.7.330738. PMID: 330738.

Loken MR, Sweet RG, Herzenberg LA. Cell discrimination by multiangle light scattering. J Histochem Cytochem. 1976 Jan;24(1):284-91. doi: 10.1177/24.1.1254923. PMID: 1254923.

Loken MR, Herzenberg LA. Analysis of cell populations with a fluorescence-activated cell sorter. Ann N Y Acad Sci. 1975 Jun 30;254:163-71. doi: 10.1111/j.1749-6632.1975.tb29166.x. PMID: 52308.

Flow Cytometry

Cutler, J. & Stolk, T. & Eidenschink Brodersen, Lisa & Wells, Denise & Loken, M. (2011). 113 Flow cytometric analysis of erythropoiesis: The last major frontier. Leukemia Research - LEUK RES. 35. 10.1016/S0145-2126(11)70115-1.

Loken, M.R. and Hudson, C.A., 2024. Measuring response to therapy in AML: Difference from normal flow cytometry vs RQ-PCR. Methods in Cell Biology, 186, pp.233-247.

Li CC, **Loken MR**, Kao RH, Wang TF, Tsai HH, Hsu SM, et al. Multidimensional flow cytometry for detection of rare populations in hematological malignancies. Tzu Chi Med J 2009;21:40–51.

Loken MR, Chu SC, **Fritschle W**, **Kalnoski M**, **Wells DA**. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom. 2009 Jan;76(1):27-36. doi: 10.1002/cyto.b.20429. Epub 2008 Jun 11. PMID: 18548614.

Wells DA, **Loken MR**. Flow cytometric mean fluorescence intensity: the biophysics behind the number. Leuk Res. 2008 Jun;32(6):845-6. doi: 10.1016/j.leukres.2007.10.002. Epub 2007 Nov 19. Erratum in: Leuk Res. 2008 Nov;32(11):1792. PMID: 18023867

Loken, Michael & Chu, Sung-Chao & Fritschle, Wayne & Li, Dian-Kun & Wells, Denise. (2007). Correcting Flow Cytometric Blast Counts for Blood Contamination in Bone Marrow Aspirates. Blood. 110. 4613-4613. 10.1182/blood.V110.11.4613.4613.

Loken MR. Multidimensional data analysis in immunophenotyping. Curr Protoc Cytom. 2001 May; Chapter 10:Unit 10.4. doi: 10.1002/0471142956.cy1004s00. PMID: 18770678.

Muroi K, Amemiya Y, Sievers EL, Miura Y, Hakamori SI, **Loken MR.** Expression of sialosyl-T and disialosyl-T antigens in erythroid cells. Leuk Lymphoma. 1997 May;25(5-6):403-14. doi: 10.3109/10428199709039027. PMID: 9250810.

Wells, Denise & Daigneault-Creech, Celeste & Simrell, Charles. (1992). Effect of Iron Status on Reticulocyte Mean Channel Fluorescence. American journal of clinical pathology. 97. 130-4. 10.1093/ajcp/97.1.130.

Terstappen LW, Johnson D, Mickaels RA, Chen J, Olds G, Hawkins JT, **Loken MR,** Levin J. Multidimensional flow cytometric blood cell differentiation without erythrocyte lysis. Blood Cells. 1991;17(3):585-602; discussion 603-5. PMID: 1722123.

Civin CI, Strauss LC, Fackler MJ, Trischmann TM, Wiley JM, **Loken MR.** Positive stem cell selection--basic science. Prog Clin Biol Res. 1990;333:387-401; discussion 402. PMID: 1689854.

Loken, Michael R., Jeanne M. Brosnan, Bruce A. Bach, and Kenneth A. Ault. "Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry." *Cytometry: The Journal of the International Society for Analytical Cytology* 11, no. 4 (1990): 453-459.

Terstappen LW, **Loken MR.** Five-dimensional flow cytometry as a new approach for blood and bone marrow differentials. Cytometry. 1988 Nov;9(6):548-56. doi: 10.1002/cyto.990090607. PMID: 3208621.

Terstappen LW, Shah VO, Conrad MP, Recktenwald D, **Loken MR.** Discriminating between damaged and intact cells in fixed flow cytometric samples. Cytometry. 1988 Sep;9(5):477-84. doi: 10.1002/cyto.990090512. PMID: 2460298.

Hollander Z, **Loken MR.** Simultaneous analysis of DNA content and surface antigens in human bone marrow. Cytometry. 1988 Sep;9(5):485-90. doi: 10.1002/cyto.990090513. PMID: 3180949.

Civin CI, **Loken MR.** Cell surface antigens on human marrow cells: dissection of hematopoietic development using monoclonal antibodies and multiparameter flow cytometry. Int J Cell Cloning. 1987 Jul;5(4):267-88. doi: 10.1002/stem.5530050403. PMID: 3305726.

Civin CI, Banquerigo ML, Strauss LC, **Loken MR.** Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10-positive progenitor cells in normal human bone marrow. Exp Hematol. 1987 Jan;15(1):10-7. PMID: 3096755. **CD34 Progenitor Cells**

Loken MR, Keji JF, Kelley KA. Comparison of helium-neon and dye lasers for the excitation of allophycocyanin. Cytometry. 1987 Jan;8(1):96-100. doi: 10.1002/cyto.990080114. PMID: 3542436.

Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH, **Loken MR,** Civin CI. Antigenic analysis of hematopoiesis. IV. The My-11 hematopoietic cell surface antigen is expressed by myelomonocytic and lymphoid, but not erythroid, progenitor cells. Exp Hematol. 1986 Nov;14(10):935-45. PMID: 3464448.

Houck DW, **Loken MR.** Simultaneous analysis of cell surface antigens, bromodeoxyuridine incorporation and DNA content. Cytometry. 1985 Nov;6(6):531-8. doi: 10.1002/cyto.990060607. PMID: 2866070.

Dialynas DP, Wilde DB, Marrack P, Pierres A, Wall KA, Havran W, Otten G, **Loken MR**, Pierres M, Kappler J, et al. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev. 1983;74:29-56. doi: 10.1111/j.1600-065x.1983.tb01083.x. PMID: 6195085.

Sarmiento M, Dialynas DP, Lancki DW, Wall KA, Lorber MI, **Loken MR**, Fitch FW. Cloned T lymphocytes and monoclonal antibodies as probes for cell surface molecules active in T cell-mediated cytotoxicity. Immunol Rev. 1982;68:135-69. doi: 10.1111/j.1600-065x.1982.tb01063.x. PMID: 6184304.

Glasebrook AL, Sarmiento M, **Loken MR**, Dialynas DP, Quintans J, Eisenberg L, Lutz CT, Wilde D, Fitch FW. Murine T lymphocyte clones with distinct immunological functions. Immunol Rev. 1981;54:225-66. doi: 10.1111/j.1600-065x.1981.tb00439.x. PMID: 6166535.

Loken MR. Evaluating optical filter efficiency in a flow cytometer. J Histochem Cytochem. 1980 Oct;28(10):1136-7. doi: 10.1177/28.10.6999085. PMID: 6999085.

Murphy DB, Jones PP, **Loken MR**, McDevitt HO. Interaction between I region loci influences the expression of a cell surface Ia antigen. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5404-8. doi: 10.1073/pnas.77.9.5404. PMID: 6776536; PMCID: PMC350067.

Loken MR. Separation of viable T and B lymphocytes using a cytochemical stain. Hoechst 33342. J Histochem Cytochem. 1980 Jan;28(1):36-9. doi: 10.1177/28.1.6153191. PMID: 6153191

Leibson PJ, **Loken MR**, Shapiro SJ, Schreiber H. Direct determination of the influence of the cell cycle on the survival of tumor cells exposed to cytotoxic antibodies. Cancer Res. 1980 Jan;40(1):56-60. PMID: 7349903.

Loken MR, Parks DR, Herzenberg LA. Identification of cell asymmetry and orientation by light scattering. J Histochem Cytochem. 1977 Jul;25(7):790-5. doi: 10.1177/25.7.330730. PMID: 330730.

Herzenberg LA, Herzenberg LA, Black SJ, **Loken MR**, Okumura K, van der Loo W, Osborne BA, Hewgill D, Goding JW, Gutman G, Warner NL. Surface markers and functional relationships of cells involved in murine B-lymphocyte differentiation. Cold Spring Harb Symp Quant Biol. 1977;41 Pt 1:33-45. doi: 10.1101/sqb.1977.041.01.007. PMID: 408094.

Lymphocyte Subsets

Loken MR, Owens MA, Stelzer GT, Lister A, Siragusa M, Morrow C: Flow Cytometric Immunophenotyping Quality Assurance and Quality Control. Procedures for CD4+ T lymphocyte Subset Determinations. Lecture Series. Centers for Disease Control and Prevention Atlanta, 1994

Loken MR, Owens MA, Stelzer GT, Lister A, Siragusa M, Morrow C: Flow Cytometric Immunophenotyping Quality Assurance and Quality Control. Procedures for CD4+ T lymphocyte Subset Determinations. Self-Study Guide, Centers for Disease Control and Prevention, Atlanta, 1994

Loken MR, Brosnan JM, Bach BA, Ault KA. Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. Cytometry. 1990;11(4):453-9. doi: 10.1002/cyto.990110402. PMID: 1693112.

Watkins JR, **Loken MR**, Knight KL. Two B-cell subpopulations identified by flow cytometry. Immunology. 1985 Oct;56(2):315-20. PMID: 3876983; PMCID: PMC1453683.

Lanier LL, **Loken MR**. Human lymphocyte subpopulations identified by using three-color immunofluorescence and flow cytometry analysis: correlation of Leu-2, Leu-3, Leu-7, Leu-8, and Leu-11 cell surface antigen expression. J Immunol. 1984 Jan;132(1):151-6. PMID: 6361119.

Loken MR, Lanier LL. Three-color immunofluorescence analysis of Leu antigens on human peripheral blood using two lasers on a fluorescence-activated cell sorter. Cytometry. 1984 Mar;5(2):151-8. doi: 10.1002/cyto.990050209. PMID: 6370629.

Sarmiento M, **Loken MR**, Trowbridge IS, Coffman RL, Fitch FW. High molecular weight lymphocyte surface proteins are structurally related and are expressed on different cell populations at different times during lymphocyte maturation and differentiation. J Immunol. 1982 Apr;128(4):1676-84. PMID: 6460808.

Dessner DS, **Loken MR**. DNL 1.9: a monoclonal antibody which specifically detects all murine B lineage cells. Eur J Immunol. 1981 Apr;11(4):282-5. doi: 10.1002/eji.1830110403. PMID: 6788569.

Antigenic Analysis of Normal Bone Marrow

Eidenschink Brodersen L, Menssen AJ, Wangen JR, Stephenson CF, **de Baca ME, Zehentner BK, Wells DA, Loken MR**. Assessment of erythroid dysplasia by "difference from normal" in routine clinical flow cytometry work-up. Cytometry B Clin Cytom. 2014 Oct 21. doi: 10.1002/cytob.21199. Epub ahead of print. PMID: 25336233.

Wangen JR, **Eidenschink Brodersen L**, Stolk TT, **Wells DA, Loken MR**. Assessment of normal erythropoiesis by flow cytometry: important considerations for specimen preparation. Int J Lab Hematol. 2014 Apr;36(2):184-96. doi: 10.1111/ijlh.12151. Epub 2013 Oct 3. PMID: 24118926.

Loken MR. Multidimensional data analysis in immunophenotyping. Curr Protoc Cytom. 2001 May; Chapter 10:Unit 10.4. doi: 10.1002/0471142956.cy1004s00. PMID: 18770678.

Wells DA, Sale GE, Shulman HM, Myerson D, Bryant EM, Gooley T, **Loken MR**. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol. 1998 Jul;110(1):84-94. doi: 10.1093/ajcp/110.1.84. PMID: 9661926.

Stelzer GT, Shults KE, **Loken MR**. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci. 1993 Mar 20;677:265-80. doi: 10.1111/j.1749-6632.1993.tb38783.x. PMID: 8494214.

Loken MR, Terstappen LW, Civin CI, Fackler MJ. Flow cytometric characterization of erythroid, lymphoid and monomyeloid lineages in normal human bone marrow. In: Laerum OD, Bjerksnes R, editors. Flow cytometry in hematology. New York: Academic Press; 1992. p. 31-42.

Terstappen LWMM, **Loken MR**: Leukocyte differential counting. in Flow Cytometry in Hematology Laerum OD and Bjerksnes R eds. Academic Press, New York, pp 95-110, 1992

Terstappen LW, Huang S, Safford M, Lansdorp PM, **Loken MR**. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood. 1991 Mar 15;77(6):1218-27. PMID: 1705833.

Terstappen LW, Johnsen S, Segers-Nolten IM, **Loken MR**. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood. 1990 Nov 1;76(9):1739-47. PMID: 2224123.

Terstappen LW, Safford M, **Loken MR**. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia. 1990 Sep;4(9):657-63. PMID: 2395385.

Terstappen LW, Hollander Z, Meiners H, **Loken MR**. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol. 1990 Aug;48(2):138-48. doi: 10.1002/jlb.48.2.138. PMID: 2196321.

Terstappen LW, **Loken MR**. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol. 1990 Jul;2(4):229-40. PMID: 1703434.

LeBien TW, Wörmann B, Villablanca JG, Law CL, Steinberg LM, Shah VO, **Loken MR**. Multiparameter flow cytometric analysis of human fetal bone marrow B cells. Leukemia. 1990 May;4(5):354-8. PMID: 1697009.

Terstappen LWMM, Segers-Nolten I, Safford M, Shah VO, **Loken MR**. Monomyeloid cell differentiation in normal bone marrow assessed by multidimensional flow cytometry. In: Burger G, Oberholzer M, Vooijs G.P., ed. Advances in Analytical Cellular Pathology. Amsterdam: Excerpta Medica; 1990:211-2.

Terstappen LW, Hollander Z, Meiners H, **Loken MR**. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol. 1990 Aug;48(2):138-48. doi: 10.1002/jlb.48.2.138. PMID: 2196321.

Terstappen L, **Loken M**. Multi-dimensional flow cytometric characterization of myeloid maturation in normal bone marrow and acute myeloid leukemia. In: Burger G, Oberholzer M, Vooijs G, eds. Advances in Analytical Cellular Pathology. Amsterdam, The Netherlands: Excerpta Medica; 1990:209-210

Terstappen LW, **Loken MR**. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol. 1990 Jul;2(4):229-40. PMID: 1703434.

Terstappen LW, Segers-Nolten I, Safford M, Shah VO, **Loken MR**. Monomyeloid cell differentiation in normal bone marrow assessed by multidimensional flow cytometry. In: Burger MO G, Vooijs GP, editors. Advances in analytical cellular pathology: proceedings of the first conference of the European society for analytical cellular pathology. Amsterdam: Excerpta Medica; 1990. p. 211–2.

Terstappen L, Shah V, Civin C, Hurwitz C, **Loken M**. Multidimensional flow cytometry as a new approach for discrimination between normal and leukemic cells in peripheral blood and bone marrow. In: Jansen A, editor. Progress in Cytometry II: Flow and Image. Erembodegen, Belgium: Becton-Dickinson; 1989. pp 4–29.

Shah VO, Civin CI, **Loken MR**. Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis. J Immunol. 1988 Mar 15;140(6):1861-7. PMID: 2964486.

Hollander Z, Shah VO, Civin CI, **Loken MR**. Assessment of proliferation during maturation of the B lymphoid lineage in normal human bone marrow. Blood. 1988 Feb;71(2):528-31. PMID: 3257397.

Loken MR, Shah VO, Hollander Z, Civin CI. Flow cytometric analysis of normal B lymphoid development. Pathol Immunopathol Res. 1988;7(5):357-70. doi: 10.1159/000157129. PMID: 3266012.

Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood. 1987 Nov;70(5):1316-24. PMID: 3117132.

Loken MR, Civin CI, Bigbee WL, Langlois RG, Jensen RH. Coordinate glycosylation and cell surface expression of glycophorin A during normal human erythropoiesis. *Blood*. 1987 Dec;70(6):1959-61. PMID: 2445402.

Civin CI, **Loken MR**. Cell surface antigens on human marrow cells: dissection of hematopoietic development using monoclonal antibodies and multiparameter flow cytometry. *Int J Cell Cloning*. 1987 Jul;5(4):267-88. doi: 10.1002/stem.5530050403. PMID: 3305726.

Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow: I. Normal erythroid development. *Blood*. 1987 Jan;69(1):255-63. PMID: 2947644.

Lanier LL, Le AM, Civin CI, **Loken MR**, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. *J Immunol*. 1986 Jun 15;136(12):4480-6. PMID: 3086432.

Loken MR: Cell surface antigen and morphological characterization of leucocyte populations by flow cytometry. *Methods Hematol*, 52 (1985), p. 123

Leukemia

T-cell LGL Leukemia

Singleton TP, Yin B, Teferra A, Mao JZ. Spectrum of Clonal Large Granular Lymphocytes (LGLs) of $\alpha\beta$ T Cells: T-Cell Clones of Undetermined Significance, T-Cell LGL Leukemias, and T-Cell Immunoclonones. *Am J Clin Pathol*. 2015 Jul;144(1):137-44. doi: 10.1309/AJCPJ57YTEGLIUOI. PMID: 26071471.

ALL

Lyvannak, S., Sereyleak, B., Heng, S., Bunpaov, T., Sothearak, H., Keller, F.G., Burke, M.J., Watkins, B., **Loken, M.R.**, Brodersen, L.E. and **Hudson, C.A.**, 2025. Introduction of Treatment for Children with Acute Lymphoblastic Leukemia in a Resource Limited Hospital in Cambodia. *Blood Global Hematology*. 2025;1(2):100011. doi:https://doi.org/10.1016/j.bglo.2025.100011.

Ragg S, **Zehentner BK**, **Loken MR**, Croop JM. Evidence for BCR/ABL1-positive T-cell acute lymphoblastic leukemia arising in an early lymphoid progenitor cell. *Pediatr Blood Cancer*. 2019 Sep;66(9):e27829. doi: 10.1002/pbc.27829. Epub 2019 May 28. PMID: 31136068.

Doney K, **Loken M**, Bryant E, Smith A, Appelbaum F. Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL. *Bone Marrow Transplant*. 2008 Aug;42(4):271-4. doi: 10.1038/bmt.2008.155. Epub 2008 May 26. PMID: 18500370; PMCID: PMC3044127.

Bradfield SM, Radich JP, **Loken MR**. Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection. *Leukemia*. 2004 Jun;18(6):1156-8. doi: 10.1038/sj.leu.2403352. PMID: 15042107

Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, **Loken MR**, Hawkins DS. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. *Pediatr Blood Cancer*. 2004 Oct;43(5):571-9. doi: 10.1002/pbc.20128. PMID: 15382275.

Meshinchi S, Thomson B, Finn LS, Leisenring W, Green C, Radich JP, **Loken M**, Hawkins D. Comparison of multidimensional flow cytometry with standard morphology for evaluation of early marrow response in pediatric acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2001 Dec;23(9):585-90. doi: 10.1097/00043426-200112000-00007. Erratum in: J Pediatr Hematol Oncol 2002 Feb;24(2):165. PMID: 11902302.

Hurwitz CA, **Loken MR**, Graham ML, Karp JE, Borowitz MJ, Pullen DJ, Civin CI. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood. 1988 Jul;72(1):299-307. PMID: 3291983.

Myelodysplasia

Jacoby MA, Duncavage ED, Khanna A, Chang GS, Nonavinkere Srivatsan S, Miller CA, Gao F, Robinson J, Shao J, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Brendel K, Chavez M, DiPersio JF, Abboud CN, Stockerl-Goldstein K, Westervelt P, Cashen A, Pusic I, Oh ST, Welch JS, **Wells DA**, **Loken MR**, Uy GL, Walter MJ. Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response. Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02426-0. Epub ahead of print. PMID: 39367170.

Sridhar Nonavinkere Srivatsan , Monique Chavez , Christopher Miller , **Andrew Menssen** , Ajay Khanna , Catrina Fronick,, Robert Fulton , Sharon Heath , Constantine Logothetis , Tasha Burton , Victoria Donaldson , Claudia Cabrera , Ravi Vij , Eric Duncavage , Jin Shao , Raya Saba , Megan Jacoby , Matthew J. Walter. Reduced subclone diversity in clonal cytopenia of undetermined significance compared to myelodysplastic syndromes; <https://doi.org/10.1016/j.cancergen.2024.08.010>.

Cutler JA, Pugsley HR, **Bennington R**, **Fritschle W**, **Hartmann L**, **Zaidi N**, **Menssen AJ**, **Singleton TP**, **Xu D**, **Loken MR**, **Wells DA**, **Brodersen LE**, **Zehentner BK**. Integrated analysis of genotype and phenotype reveals clonal evolution and cytogenetically driven disruption of myeloid cell maturation in myelodysplastic syndromes. Cytometry B Clin Cytom. 2023 Mar;104(2):183-194. doi: 10.1002/cyto.b.22036. Epub 2021 Nov 13. PMID: 34773362.

Monique Chavez, Sridhar N Srivatsan, Christopher A Miller, **Andrew J. Menssen**, Ajay Khanna, Jin Shao, Catrina Fronick, Robert Fulton, Sharon E Heath, Constantine Logothetis, Tasha Burton, Victoria Donaldson, Claudia Cabrera, Raya Saba, Kiran R. Vij, Eric J. Duncavage, Meagan Jacoby, Matthew J. Walter, Reduced Subclone Diversity in Clonal Cytopenia of Undetermined Significance Compared to Myelodysplastic Syndrome, Blood, Volume 142, Supplement 1, 2023, Page 2696, ISSN 0006-4971.

van der Velden, V. H. J., Preijers, F., Johansson, U., Westers, T. M., Dunlop, A., Porwit, A., Béné, M. C., Valent, P., te Marvelde, J., Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W., Chapuis, N., Fontenay, M., Bettelheim, P., **Eidenschink-Brodersen, L.**, Font, P., **Loken, M. R.**, Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., **Wells, D. A.**, Della Porta, M. G., Burbury, K., Bellos, F., Weiß, E., Kern, W., & van de Loosdrecht, A. (2023). Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet. Cytometry Part B: Clinical Cytometry, 104(1), 15–26.

van de Loosdrecht, A. A., Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W., Preijers, F., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., **Eidenschink-Brodersen, L.**, Font, P., Johansson, U., **Loken, M. R.**, ... Ireland, R. (2023). Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group. Cytometry Part B: Clinical Cytometry, 104(1), 77–86.

Porwit A, Béné MC, Deutz C, Matarraz S, Oelschlaegel U, Westers TM, Wagner-Ballon O, Kordasti S, Valent P, Preijers F, Alhan C, Bellos F, Bettelheim P, Burbury K, Chapuis N, Cremers E, Della Porta MG, Dunlop A, **Eidenschink-Brodersen L**, Font P, Fontenay M, Hobo W, Ireland R, Johansson U, **Loken MR**, Ogata K, Orfao A, Psarra K, Saft L, Subira D, Te Marvelde J, **Wells DA**, van der Velden VHJ, Kern W, van de Loosdrecht AA Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group. *Cytometry B Clin Cytom*. 2023 Jan;104(1):27-50. doi: 10.1002/cyto.b.22108. Epub 2022 Dec 20. PMID: 36537621

van der Velden VHJ, Preijers F, Johansson U, Westers TM, Dunlop A, Porwit A, Béné MC, Valent P, Te Marvelde J, Wagner-Ballon O, Oelschlaegel U, Saft L, Kordasti S, Ireland R, Cremers E, Alhan C, Duetz C, Hobo W, Chapuis N, Fontenay M, Bettelheim P, **Eidenschink-Brodersen L**, Font P, **Loken MR**, Matarraz S, Ogata K, Orfao A, Psarra K, Subirá D, **Wells DA**, Della Porta MG, Burbury K, Bellos F, Weiß E, Kern W, van de Loosdrecht A. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet. *Cytometry B Clin Cytom*. 2021 Dec 11. doi: 10.1002/cyto.b.22046. Epub ahead of print. PMID: 34894176.

Cutler, J. A., Pugsley, H. R., Bennington, R., Fritschle, W., Hartmann, L., Zaidi, N., Menssen, A. J., Singleton, T. P., Xu, D., Loken, M. R., Wells, D. A., Brodersen, L. E., & Zehentner, B. K. (2021). Integrated analysis of genotype and phenotype reveals clonal evolution and cytogenetically driven disruption of myeloid cell maturation in myelodysplastic syndromes. *Cytometry Part B: Clinical Cytometry*, 1–12. <https://doi.org/10.1002/cyto.b.22036>

Curtis A Lachowicz, Joshua F Zeidner, **Ashley M. Eckel**, Daniel T Peters, Jacob Fang, Amenech Ashango, Andy Kaempf, Fangyan Dai, Christopher A. Eide, Stephen E. Kurtz, Theodore P Braun, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Daniel A Pollyea, Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML, *Blood*, Volume 144, Supplement 1, 2024, Page 62.

Danielle C. Kirkey, Anisha M. Loeb, Sommer Castro, Cyd Nourigat McKay, LaKeisha Perkins, **Laura Pardo**, Amanda R. Leonti, Thao T. Tang, **Michael R. Loken, Lisa Eidenschink Brodersen**, Keith R. Loeb, David A. Scheinberg, Quy Le, Soheil Meshinchi; Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia. *Blood Adv* 2023; 7 (7): 1178–1189.

Xu, Dongbin & Eidenschink Brodersen, Lisa & Hammock, Kelle & Wells, Denise & Loken, Michael & Zehentner, Barbara. (2017). SNP/CGH Microarray Analysis in MDS: Correlation with Conventional Cytogenetic, FISH and Flow-Cytometric Findings. *Cancer Genetics*. 214-215. 51-52. 10.1016/j.cancergen.2017.04.063.

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, **Wells DA**, Giagounidis A, **Loken M**, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. *Oncotarget*. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. PMID: 29088721; PMCID: PMC5650276.

Zehentner, B., Brodersen, L., Stephenson, C., Cutler, J., de Baca, M., Menssen, A., Hammock, K., Johnson, K., Hartmann, L., Loken, M. and Wells, D., 2015. 169 SNP/CGH MICROARRAY ANALYSIS IN MDS: CORRELATION WITH CONVENTIONAL CYTOGENETICS, FISH AND FLOW CYTOMETRIC FINDINGS. *Leukemia Research*, 39, p.S86.

Zehentner, Barbara & Cutler, Jevon & Hartmann, Luise & Johnson, Krystal & Bennington, Richard & Fritschle, Wayne & Ghirardelli, Keely & Brodersen, Lisa & Chapman, Doug & Stephenson, Christine & de Baca, Monica & Singleton, Timothy & Wells, Denise & Loken, Michael. (2014). Myeloid Cell Maturation Is Disrupted by Monosomy 7 or By Gain of Additional Genetic Aberrations during Clonal Evolution in Myelodysplastic Syndromes *Blood*, Volume 124, Issue 21, 2014, Page 3244, ISSN 0006-4971, <https://doi.org/10.1182/blood.V124.21.3244.3244>.

Porwit A, van de Loosdrecht AA, Bettelheim P, **Brodersen LE**, Burbury K, Cremers E, Della Porta MG, Ireland R, Johansson U, Matarraz S, Ogata K, Orfao A, Preijers F, Psarra K, Subirá D, Valent P, van der Velden VH, **Wells D**, Westers TM, Kern W, Béné MC. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. *Leukemia*. 2014 Sep;28(9):1793-8. doi: 10.1038/leu.2014.191. Epub 2014 Jun 12. PMID: 24919805.

Eidenschink Brodersen, Lisa & Menssen, Andrew & Zehentner, Barbara & Stephenson, Christine & de Baca, Monica & Johnson, Krystal & Singleton, Timothy & Hartmann, Luise & Loken, Michael & Wells, Denise. (2014). A Comparative Assessment of Flow Cytometric Scoring Systems in MDS. *Blood*. 124. 5589-5589. 10.1182/blood.V124.21.5589.5589.

Eidenschink Brodersen, Lisa & Zehentner, Barbara & Hartmann, L. & Ghiradelli, K. & Wells, Denise & Loken, M.R. (2013). P-050 Flow cytometry combined with SNP/CGH array can definitively identify myelodysplastic syndromes in patients with unexplained cytopenias. *Leukemia Research*. 37. S44. 10.1016/S0145-2126(13)70099-7.

van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, **Eidenschink L**, Cazzola M, Chu SS, Cullen M, **Cutler JA**, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, **Loken MR**, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, **Wells DA**, de Witte TM, Zettl F, Béné MC, Westers TM. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. *Leuk Lymphoma*. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. PMID: 22916713.

Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, **Cutler JA**, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, **Loken MR**, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, **Wells DA**, Zettl F, Béné MC, van de Loosdrecht AA. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. *Leukemia*. 2012 Jul;26(7):1730-41. doi: 10.1038/leu.2012.30. Epub 2012 Feb 6. PMID: 22307178.

Wells, Denise & Loken, Michael. (2012). Response to “Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome”. *Annals of Hematology*. 91. 10.1007/s00277-012-1504-4.

Chu SC, Wang TF, Li CC, Kao RH, Li DK, Su YC, **Wells DA**, **Loken MR**. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes. *Leuk Res*. 2011 Jul;35(7):868-73. doi: 10.1016/j.leukres.2011.02.016. Epub 2011 Mar 12. PMID: 2139794

Cutler, J.A., Wells, D.A., van de Loosdrecht, A.A., de Baca, M.E., Kalnoski, M.H., Zehentner, B.K., Refining Prognostication for MDS by Flow Cytometry

Cutler JA, Wells DA, van de Loosdrecht AA, **de Baca ME**, **Kalnoski MH**, **Zehentner BK**, **Eidenschink L**, **Ghiradelli KM**, **Biggerstaff JS**, **Loken MR**. Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias. *Cytometry B Clin Cytom*. 2011 May;80(3):150-7. doi: 10.1002/cyto.b.20582. Epub 2010 Dec 23. PMID: 21520402.

van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, **Wells DA, Loken MR**, Westers TM. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009 Aug;94(8):1124-34. doi: 10.3324/haematol.2009.005801. Epub 2009 Jun 22. PMID: 19546437; PMCID: PMC2719035.

Scott BL, **Wells DA, Loken MR**, Myerson D, Leisenring WM, Deeg HJ. Validation of a flow cytometric scoring system as a prognostic indicator for post-transplantation outcome in patients with myelodysplastic syndrome. Blood. 2008 Oct 1;112(7):2681-6. doi: 10.1182/blood-2008-05-153700. Epub 2008 Jul 7. PMID: 18606877; PMCID: PMC2556605.

Wells, Denise & Loken, M.R. (2008). Diagnostic and prognostic utility of flow cytometry in MDS.

Loken MR, van de Loosdrecht A, Ogata K, Orfao A, **Wells DA**. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res. 2008 Jan;32(1):5-17. doi: 10.1016/j.leukres.2007.04.020. Epub 2007 Jun 18. PMID: 17576013.

Loken MR, Wells DA. The role of flow cytometry in myelodysplastic syndromes. J Natl Compr Canc Netw. 2008 Oct;6(9):935-41. doi: 10.6004/jnccn.2008.0071. PMID: 18926102.

Wells DA, Ogata K. On flow cytometry in myelodysplastic syndromes, with caveats. Leuk Res. 2008 Feb;32(2):209-10. doi: 10.1016/j.leukres.2007.07.024. Epub 2007 Sep 7. PMID: 17825408.

Loken MR, Wells DA. The role of flow cytometry in myelodysplastic syndromes. J Natl Compr Canc Netw. 2008 Oct;6(9):935-41. doi: 10.6004/jnccn.2008.0071. PMID: 18926102

Loken MR, van de Loosdrecht A, Ogata K, Orfao A, **Wells DA**. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res. 2008 Jan;32(1):5-17. doi: 10.1016/j.leukres.2007.04.020. Epub 2007 Jun 18. PMID: 17576013.

Wells, Denise & Scott, Bart & Leisenring, Wendy & Loken, Michael & Deeg, HJ. (2007). Myeloid Dyspoiesis as Determined by Flow Cytometry Is a More Powerful Predictor of Post-Transplant Relapse with MDS Than the Marrow Myeloblast Count. Blood. 110. 1656-1656. 10.1182/blood.V110.11.1656.1656.

Valent, Peter & Horny, Hans-Peter & Bennett, John & Fonatsch, Christa & Germing, Ulrich & Greenberg, Peter & Haferlach, Torsten & Haase, Detlef & Kolb, Hans-Jochen & Krieger, Otto & **Loken, Michael & Loosdrecht, Arjan & Ogata, Kiyoyuki & Orfao, Alberto & Pfeilstöcker, Michael & Rüter, Björn & Sperr, Wolfgang & Stauder, Reinhard & Wells, Denise.** (2007). Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leukemia research. 31. 727-36. 10.1016/j.leukres.2006.11.009.

Loken, M & Benesch, M & Deeg, HJ & Wells, Denise. (2004). A flow cytometric scoring system for myeloid and monocytic aberrancies to enhance diagnostic and prognostic accuracy in myelodysplastic syndromes. 58-58. May 2004. **Cytometry.** Conference: 22nd Congress of the International-Society-for-Analytical-Cytology, Volume: 59A

Scott BL, Storer B, **Loken MR**, Storb R, Appelbaum FR, Deeg HJ. Pretransplantation induction chemotherapy and post-transplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2005 Jan;11(1):65-73. doi: 10.1016/j.bbmt.2004.10.001. PMID: 15625546. **Patients with increased blasts do not improve outcome with chemotherapy before transplant.**

Wells DA, Benesch M, **Loken MR**, Vallejo C, Myerson D, Leisenring WM, Deeg HJ. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. *Blood*. 2003 Jul 1;102(1):394-403. doi: 10.1182/blood-2002-09-2768. Epub 2003 Mar 20. PMID: 12649150.

Benesch M, Deeg HJ, **Wells D**, **Loken M**. Flow cytometry for diagnosis and assessment of prognosis in patients with myelodysplastic syndromes. *Hematology*. 2004 Jun;9(3):171-7. doi: 10.1080/10245330410001701521. PMID: 15204098.

Benito AI, Bryant E, **Loken MR**, Sale GE, Nash RA, John Gass M, Deeg HJ. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. *Leuk Res*. 2003 May;27(5):425-36. doi: 10.1016/s0145-2126(02)00221-7. PMID: 12620294.

Zang DY, Goodwin RG, **Loken MR**, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. *Blood*. 2001 Nov 15;98(10):3058-65. doi: 10.1182/blood.v98.10.3058. PMID: 11698291.

Deeg HJ, Beckham C, **Loken MR**, Bryant E, Lesnikova M, Shulman HM, Gooley T. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. *Leuk Lymphoma*. 2000 Apr;37(3-4):405-14. doi: 10.3109/10428190009089441. PMID: 10752992.

Cooper LJ, Shannon KM, **Loken MR**, Weaver M, Stephens K, Sievers EL. Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. *Blood*. 2000 Sep 15;96(6):2310-3. PMID: 10979983.

Wells DA, Hall MC, Shulman HM, **Loken MR**. Occult B cell malignancies can be detected by three-color flow cytometry in patients with cytopenias. *Leukemia*. 1998 Dec;12(12):2015-23. doi: 10.1038/sj.leu.2401219. PMID: 9844932.

Gersuk GM, Beckham C, **Loken MR**, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. *Br J Haematol*. 1998 Oct;103(1):176-88. doi: 10.1046/j.1365-2141.1998.00933.x. PMID: 9792306.

AML

Andrew Menssen, **Amenech Ashango**, Todd Alonzo, Robert Gerbing, **Maria Pardo**, **Fan-Chi Hsu**, **Loren Lott**, **Fangyan Dai**, Todd Cooper, Jessica Pollard, Katherine Tarlock, Richard Aplenc, Soheil Meshinchi, Lisa Brodersen, **Michael Loken**, **Chad Hudson**. "FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib therapy: A report from the Children's Oncology Group AAML1031 protocol." *Blood* 146 (2025): 5256.

Benjamin J. Huang, MD, Lauren K. Meyer, MD, PhD, Todd A. Alonzo, PhD, Yi-Cheng Wang, MS, Adam J. Lambie, MD, Weijie Wang, BA, Betsy Hirsch, PhD, Gordana Raca, MD, PhD, Xiaotu Ma, PhD, Alan S. Gamis, MD, Richard Aplenc, MD, PhD, E. Anders Kolb, MD, Todd M. Cooper, DO, Katherine Tarlock, MD, **Michael R. Loken**, PhD, Soheil Meshinchi, MD, PhD, Joseph H. Chewning, MD, William G. Woods, MD, and John T. Horan, MD. "Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report from the Children's Oncology Group." *Journal of Clinical Oncology* 43, no. 17 (2025): 1961-1971.

Curtis A. Lachowicz, Mael Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier-Tardy, **Fangyan Dai, Amenech B. Ashango**, Daniel T. Peters, Jacob Fang, Andy Kaempf, Nicola Long, Christopher A. Eide, Stephen E. Kurtz, Wei Xie, Anupriya Agarwal, Aishwarya Sahasrabudhe, Christine M. McMahon, Maria L. Amaya, Gabrielle Meyers, Arpita Gandhi, Jessica Leonard, Brandon Hayes-Lattin, Richard T. Maziarz, Elie Traer, Rachel J. Cook, Ronan Swords, Theodore P. Braun, Jennifer N. Saultz, **Ashley M. Eckel, Michael R. Loken**, Joshua F. Zeidner, Jeffrey W. Tyner, Daniel A. Pollyea, Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study. *Blood Cancer Discovery*. Published online May 21, 2025. doi:<https://doi.org/10.1158/2643-3230.bcd-24-0256>

Jessica Hochberg, Javier Oesterheld, Aliza Gardenswartz, Allyson Flower, Liana Klejmont, Jackie Basso, Qiuhi Shi, Lauren Harrison, Michael J. Borowitz, **Michael R. Loken**, Mitchell S. Cairo, Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trial. *eClinicalMedicine*. 2025;83:103211. doi:<https://doi.org/10.1016/j.eclinm.2025.103211>

Curtis A. Lachowicz, Mael Heiblig, Gaspar Aspas Requena, Emmanuelle Tavernier-Tardy, Fangyan Dai, Amenech B. Ashango, Daniel T. Peters, Jacob Fang, Andy Kaempf, Nicola Long, Christopher A. Eide, Stephen E. Kurtz, Wei Xie, Anupriya Agarwal, Aishwarya Sahasrabudhe, Christine M. McMahon, Maria L. Amaya, Gabrielle Meyers, Arpita Gandhi, Jessica Leonard, Brandon Hayes-Lattin, Richard T. Maziarz, Elie Traer, Rachel J. Cook, Ronan Swords, Theodore P. Braun, Jennifer N. Saultz, **Ashley M. Eckel, Michael R. Loken**, Joshua F. Zeidner, Jeffrey W. Tyner, Daniel A. Pollyea, "Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study." *Blood Cancer Discovery* (2025).

Margarita Maurer-Granofszky, Flavia Battistutta, Boutheina Bouslama, Lisa Brodersen, **Chad Hudson**, Christel Katerkamp, Pamela Scarparo, Anastasia Soboli, Jeroen te Marvelde, Barbara Buldini, Linda Fogelstrand, David Gillis, Hélène Lapillonne, **Michael Loken**, Vincent van der Velden, Nils Von Neuhoff, Lucy Wheeler, Todd Cooper, Sarah Tasian, Dirk Reinhardt, Gwen Nichols, C. Zwaan, Michael Dworzak, A novel intercontinental external quality assessment program for flow cytometric measurable residual disease assessment in pediatric AML. *Blood*. 2025;146(Supplement 1):3514-3514. doi:<https://doi.org/10.1182/blood-2025-3514>

Katherine Tarlock, Corinne Summers, Danielle Kirkey, Rhonda Ries, **Maria Pardo, Andrew Menssen, Chad Hudson**, Fola shade Otegbey, Lara Kropp, Christy Greene, Stefanie Schmuck, Armenuhi Avanesyan, Concetta Quintarelli, **Michael Loken**, Franco Locatelli, Soheil Meshinchi, Phase I study of FH FOLR1 CAR T for pediatric patients with FOLR1+/CBFA2T3::GLIS2+ relapsed or refractory Acute Myeloid Leukemia. *Blood*. 2025;146(Supplement 1):4176-4176. doi:<https://doi.org/10.1182/blood-2025-4176>

Menssen, A., Ashango, A., Alonzo, T., Gerbing, R., Pardo, M., Hsu, F.C., Lott, L., Dai, F., Cooper, T., Pollard, J. and Tarlock, K., 2025. FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib therapy: A report from the Children's Oncology Group AAML1031 protocol. *Blood*, 146, p.5256.

Caitlin Elgarten, Todd Alonzo, Robert Gerbing, John Choi, Brian Fisher, Betsy Hirsch, Samir Kahwash, John Levine, Lisa Brodersen, **Michael Loken**, Susana Raimondi⁰, Katherine Tarlock, Andrew Wood, Lillian Sung, Todd Cooper, Alan Gamis, Soheil Meshinchi, Richard Aplenc, Jessica Pollard Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031. *Blood*. 2025;146(Supplement 1):1644-1644. doi:<https://doi.org/10.1182/blood-2025-1644>

Madan A, Anerao A, Mucker D, Giovanetti C, Frediani J, Morris J, Kim J, Nael A, Sassoon A, **Burnworth B, Eckel AM, Loken MR**, Chavan R. Emergence and Implications of DNMT3A Mutations in Pediatric AML Post-HSCT: A Case Report and Literature Review. *Pediatr Blood Cancer*. 2025 Oct;72(10):e31905. doi: 10.1002/pbc.31905. Epub 2025 Jul 21. PMID: 40692214.

Huang BJ, Meyer LK, Alonzo TA, Wang YC, Lambie AJ, Ries RE, Wang W, Hirsch B, Raca G, Ma X, Gamis AS, Aplenc R, Kolb EA, Cooper TM, Tarlock K, **Loken MR**, Meshinchi S, Chewing JH, Woods WG, Horan JT. Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report from the Children's Oncology Group. *J Clin Oncol*. 2025 Apr 28;JCO2401841. doi: 10.1200/JCO-24-01841. Epub ahead of print. PMID: 40294366.

Bhagwat AS, Torres L, Shestova O, Shestov M, Mellors PW, Fisher HR, Farooki SN, Frost BF, **Loken MR**, Gaymon AL, Frazee D, Rogal W, Frey N, Hexner EO, Luger SM, Loren AW, Martin ME, McCurdy SR, Perl AE, Stadtmauer EA, Brogdon JL, Fraietta JA, Hwang WT, Siegel DL, Plesa G, Aplenc R, Porter DL, June CH, Gill SI. Cytokine-mediated CAR T therapy resistance in AML. *Nat Med*. 2024 Dec;30(12):3697-3708. doi: 10.1038/s41591-024-03271-5. Epub 2024 Sep 27. PMID: 39333315.

Vivek M. Shastri, PhD, Francisco Marchi, BS, Michael R. Loken, PhD, Jatinder K. Lamba, PhD. Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients; The 66th ASH Annual Meeting Abstracts POSTER ABSTRACTS 618.ACUTE MYELOID LEUKEMIAS: BIOMARKERS AND MOLECULAR MARKERS IN DIAGNOSIS AND PROGNOSIS. *Blood* 5NOVEMBER2024|VOLUME144,NUMBERSupplement1 1543

Andrew J. Menssen, Chad A. Hudson, Todd Alonzo, Robert Gerbing, **Laura Pardo**, Amanda Leonti, Jacqueline A. Cook, Fan-Chi Hsu, Loren L. Lott, Fangyan Dai, **Collette Fearing, Keely Ghirardelli**, Tiffany Hylkema, Katherine Tarlock, Keith R. Loeb, Edward A. Kolb, Todd Cooper, Jessica Pollard, **Denise A. Wells, Michael R. Loken**, Richard Aplenc, Soheil Meshinchi, Lisa Eidenschink Brodersen; CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group. Vol. 109 No. 10 (2024): October 2024 <https://doi.org/10.3324/haematol.2023.283757>

Cook JA, Lott L, Perry J, Eckel AM, Xu D, Hudson CA, Wells DA, Loken MR, Menssen AJ. Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML. *Blood*. 2024 Aug 1;144(5):581-585. doi: 10.1182/blood.2024024264. PMID: 38749014.

Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, Hylkema TA, Castro S, Tang TT, McKay CN, Perkins L, Pardo L, Sarthy J, Beckman AK, Williams R, Idemmili R, Furlan S, Ishida T, Call L, Srivastava S, Loeb AM, Milano F, Imren S, Morris SM, Pakiam F, Olson JM, **Loken MR, Brodersen L**, Riddell SR, Tarlock K, Bernstein ID, Loeb KR, Meshinchi S. CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. *J Clin Invest*. 2024 Aug 15;134(16):e184305. doi: 10.1172/JCI184305. Erratum for: CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. PMID: 39145456; PMCID: PMC11324293.

Grace Hawkins, Danielle Kirkey, MD, Nika Panahi, BS, Melia Blankenfeld, BS, Isabel Lira, BS, Tiffany Hylkema, BS, Cyd McKay, Christina Root, Jack H. Peplinski, MSc, Logan K. Wallace, Rhonda E. Ries, MA, **Laura Pardo, MS, Michael R. Loken**, PhD, Soheil Meshinchi, MD PhD. Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia; *Blood*, 144, p.3413.

Lira, I., Kirkey, D.C., Nicolaidou, M., Muller, H., Barisa, M., Blankenfeld, M., Hawkins, G., McKay, C., Root, C., **Pardo, L. and Loken, M.R.**, 2024. Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia. *Blood*, 144, p.4793.

Stevens AM, Terrell M, Rashid R, Fisher KE, Marcogliese AN, Gaikwad A, Rao P, Vrana C, Krueger M, **Loken M, Menssen AJ, Cook JA**, Keogh N, Alozie M, Oviedo H, Gonzalez AK, Ilangoan T, Kim J, Sandhu S, Redell MS. Addressing a Pre-Clinical Pipeline Gap: Development of the Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Program at Texas Children's Hospital at Baylor College of Medicine. *Biomedicines*. 2024 Feb 8;12(2):394. doi: 10.3390/biomedicines12020394. PMID: 38397996; PMCID: PMC10886789.

Shastri, V.M., Marchi, F., **Loken, M.R.** and Lamba, J.K., 2024. Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients. *Blood*, 144, p.1543.

Grace Hawkins, Danielle Kirkey, MD, Nika Panahi, BS, Melia Blankenfeld, BS, Isabel Lira, BS, Tiffany Hylkema, BS, Cyd McKay, Christina Root, Jack H. Peplinski, MSc, Logan K. Wallace, Rhonda E. Ries, MA, **Laura Pardo, MS, Michael R. Loken**, PhD, Soheil Meshinchi, MD PhD. Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia; [https](https://doi.org/10.1182/blood-2024-144340)

Menssen AJ, Hudson CA, Alonzo T, Gerbing R, **Pardo L**, Leonti A, **Cook JA, Hsu FC, Lott LL**, Dai F, **Fearing C**, Ghirardelli K, Hylkema T, Tarlock K, Loeb KR, Kolb EA, Cooper T, Pollard J, **Wells DA, Loken MR**, Aplenc R, Meshinchi S, Brodersen LE. CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group. *Haematologica*. 2024 Oct 1;109(10):3182-3193. doi: 10.3324/haematol.2023.283757. PMID: 38299667; PMCID: PMC11443400.

Cook, J.A., Lott, L., Perry, J., Eckel, A.M., Xu, D., Hudson, C.A., Wells, D.A., Loken, M.R. and **Menssen, A.J.**, 2024. Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML. *Blood Journal*, pp.blood-2024024264.

Stevens, A.M., Terrell, M., Rashid, R., Fisher, K.E., Marcogliese, A.N., Gaikwad, A., Rao, P., Vrana, C., Krueger, **M., Loken, M. and Menssen, A.J.**, 2024. Addressing a Pre-Clinical Pipeline Gap: Development of the Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Program at Texas Children's Hospital at Baylor College of Medicine. *Biomedicines*, 12(2), p.394.

Le Q, Tang T, Leonti A, Castro S, McKay CN, Perkins L, **Pardo L**, Kirkey D, Hylkema T, Call L, Manselle M, Abrahams C, Bedard K, Molina A, **Brodersen LE, Loken MR**, Tarlock K, Meshinchi S, Loeb KR. Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia. *Blood Adv*. 2023 May 9;7(9):1666-1670. doi: 10.1182/bloodadvances.2022008303. PMID: 36595452; PMCID: PMC10182275.

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, **Michael R. Loken**, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne, Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT), *Blood*, Volume 142, Supplement 1, 2023, Page 483, ISSN 0006-4971

Jacqueline A. Cook, Loren Lott, Jenna Perry, Arun Nalla, Dongbin Xu, Chad A. Hudson, Denise A. Wells, Michael R. Loken, Andrew J. Menssen, Residual Mast Cells Can Explain Persistent Molecular Positivity in Difference from Normal Flow Cytometric-Defined MRD Negative Core Binding Factor AML, *Blood*, Volume 142, Supplement 1, 2023, Page 426, ISSN 0006-4971

Lambo, S., Trinh, D.L., Ries, R.E., Jin, D., Setiadi, A., Ng, M., Leblanc, V.G., **Loken, M.R., Brodersen, L.E., Dai, F.** and **Pardo, L.M.**, 2023. [A longitudinal single-cell atlas of treatment response in pediatric AML](#). *Cancer Cell*, 41(12), pp.2117-2135.

Jessica A. Pollard, MD; Erin Guest, MD; Todd A. Alonzo, PhD; Robert B. Gerbing, MS; **Mike R. Loken**, PhD; **Lisa Eidenschink Brodersen**, PhD; E. Anders Kolb, MD; Richard Aplenc, MD, PhD; Soheil Meshinchi, MD, PhD; Susana C. Raimondi, PhD; Betsy Hirsch, PhD; and Alan S. Gamis, MD, 2023. [Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results from the Phase III Children's Oncology Group Trial AAML0531](#), *Journal of Clinical Oncology*, Volume 39, Issue 29, 3149-3160.

Danielle C Kirkey, Melia Blankenfeld, Tiffany Hylkema, Deryk Loo, Ashley Ward, Leila Robinson, Jack H Peplinski, Logan K Wallace, **Laura Pardo**, **Andrew J. Menssen**, Rhonda E Ries, Soheil Meshinchi, [CD276 \(B7-H3\) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate](#), *Blood*, Volume 142, Supplement 1, 2023, Page 5958, ISSN 0006-4971

Danielle Kirkey, Leila Robinson, Tiffany Hylkema, Anisha Loeb, Sommer Castro, Thao Tang, Rhonda E Ries, Cyd McKay, Christina Root, **Laura Pardo**, Keith Loeb, Quy Le, Soheil Meshinchi. [Preclinical evaluation of targeting PRAME with TCR mimic CAR T cells in AML](#). DOI: 10.1200/JCO.2023.41.16_suppl.2553 *Journal of Clinical Oncology* 41, no. 16_suppl (June 01, 2023) 2553-2553.

Bertrums EJM, Smith JL, Harmon L, Ries RE, Wang YJ, Alonzo TA, **Menssen AJ**, Chisholm KM, Leonti AR, Tarlock K, Ostronoff F, Pogosova-Agadjanyan EL, Kaspers GJL, Hasle H, Dworzak M, Walter C, Muhlegger N, Morerio C, Pardo L, Hirsch B, Raimondi S, Cooper TM, Aplenc R, Gamis AS, Kolb EA, Farrar JE, Stirewalt D, Ma X, Shaw TI, Furlan SN, **Brodersen LE, Loken MR**, Van den Heuvel-Eibrink MM, Zwaan CM, Triche TJ, Goemans BF, Meshinchi S. [Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia](#). *Haematologica*. 2023 Aug 1;108(8):2044-2058. doi: 10.3324/haematol.2022.281653. PMID: 36815378; PMCID: PMC10388277.

Lambo S, Trinh DL, Ries RE, Jin D, Setiadi A, Ng M, Leblanc VG, **Loken MR, Brodersen LE, Dai F, Pardo LM**, Ma X, Vercauteren SM, Meshinchi S, Marra [A longitudinal single-cell atlas of treatment response in pediatric AML](#). *Cancer Cell*. 2023 Dec 11;41(12):2117-2135.e12. doi: 10.1016/j.ccell.2023.10.008. Epub 2023 Nov 16. PMID: 37977148.

Loeb KR, Le QH, Tang T, Castro SK, Pardo L, McKay CN, Perkins L, Smith JL, Kirkey DC, Abrahams C, Bedard K, Molina A, **Eidenschink Brodersen L, Loken MR**, Tarlock K, Meshinchi S. [Targeting FOLR1 in high-risk CBF2AT3-GLIS2 Pediatric AML with STRO-002 FOLR1-Antibody-Drug Conjugate](#). *Blood Adv*. 2022 Sep 23;bloodadvances.2022008503. doi: 10.1182/bloodadvances.2022008503. Epub ahead of print. PMID: 36149945.

Bertrums EJM, Smith JL, Harmon L, Ries RE, Wang YJ, Alonzo TA, **Menssen AJ**, Chisholm KM, Leonti AR, Tarlock K, Ostronoff F, Pogosova-Agadjanyan EL, Kaspers GJL, Hasle H, Dworzak M, Walter C, Muhlegger N, Morerio C, **Pardo L**, Hirsch B, Raimondi S, Cooper TM, Aplenc R, Gamis AS, Kolb EA, Farrar JE, Stirewalt D, Ma X, Shaw TI, Furlan SN, **Brodersen LE, Loken MR**, Van den Heuvel-Eibrink MM, Zwaan CM, Triche TJ, Goemans BF, Meshinchi S. [Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia](#). *Haematologica*. 2023 Aug 1;108(8):2044-2058. doi: 10.3324/haematol.2022.281653. PMID: 36815378; PMCID: PMC10388277.

Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, Hylkema TA, Castro S, Tang TT, McKay CN, Perkins L, Pardo L, Sarthy J, Beckman AK, Williams R, Idemmili R, Furlan S, Ishida T, Call L, Srivastava S, Loeb AM, Milano F, Imren S, Morris SM, Pakiam F, Olson JM, **Loken MR, Eidenschink Brodersen L**, Riddell SR, Tarlock K, Bernstein ID, Loeb KR, Meshinchi S. [CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target](#). *J Clin Invest*. 2022 Sep 22:e157101. doi: 10.1172/JCI157101. Epub ahead of print. PMID: 36136600.

Kirkey DC, Loeb A, Castro S, McKay CN, Perkins L, Pardo L, Leonti AR, Tang T, **Loken MR, Eidenschink Brodersen L**, Loeb KR, Scheinberg DA, Le Q, Meshinchi S. Therapeutic targeting PRAME with mTCRCAR T cells in acute myeloid leukemia. Blood Adv. 2022 Aug 19;bloodadvances.2022008304. doi: 10.1182/bloodadvances.2022008304. Epub ahead of print. PMID: 35984639.

Bertrums EJM, Smith JL, Harmon L, Ries RE, Wang YJ, Alonzo TA, Menssen AJ, Chisholm KM, Leonti AR, Tarlock K, Ostronoff F, Pogosova-Agadjanyan EL, Kaspers GJL, Hasle H, Dworzak M, Walter C, Muhlegger N, Morerio C, Pardo L, Hirsch B, Raimondi S, Cooper TM, Aplenc R, Gamis AS, Kolb EA, Farrar JE, Stirewalt D, Ma X, Shaw TI, Furlan SN, **Brodersen LE, Loken MR**, Van den Heuvel-Eibrink MM, Zwaan CM, Triche TJ, Goemans BF, Meshinchi Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023 Aug 1;108(8):2044-2058. doi: 10.3324/haematol.2022.281653. PMID: 36815378.

Pollard JA, Alonzo TA, Gerbing R, Brown P, Fox E, Choi J, Fisher B, Hirsch B, Kahwash S, Getz K, Levine J, **Brodersen LE, Loken MR**, Raimondi S, Tarlock K, Wood A, Sung L, Kolb EA, Gamis A, Meshinchi S, Aplenc R. Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Protocol AAML1031. J Clin Oncol. 2022 Mar 29;JCO2101612. doi: 10.1200/JCO.21.01612. Epub ahead of print. PMID: 35349331.

Pommert L, Cooper TM, Gerbing RB, Brodersen L, **Loken M**, Gamis A, Aplenc R, Alonzo TA, Kolb EA. Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. Cancers (Basel). 2022 Jan 26;14(3):616. doi: 10.3390/cancers14030616. PMID: 35158884; PMCID: PMC8833679.

Getz KD, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi S, Hirsch B, **Loken M, Brodersen LE**, Kahwash S, Choi J, Kolb EA, Gamis A, Aplenc R. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2022 Jan;69(1):e29313. doi: 10.1002/pbc.29313. Epub 2021 Sep 2. PMID: 34472213; PMCID: PMC8919970.

Lamble AJ, **Eidenschink Brodersen L**, Alonzo TA, Wang J, Pardo L, Sung L, Cooper TM, Kolb EA, Aplenc R, Tasian SK, **Loken MR**, Meshinchi S. CD123 Expression Is Associated with High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report from the Children's Oncology Group. J Clin Oncol. 2022 Jan 20;40(3):252-261. doi: 10.1200/JCO.21.01595. Epub 2021 Dec 2. PMID: 34855461; PMCID: PMC8769096.

Elgarten CW, Wood AC, Li Y, Alonzo TA, **Brodersen LE**, Gerbing RB, Getz KD, Huang YV, **Loken M**, Meshinchi S, Pollard JA, Sung L, Woods WG, Kolb EA, Gamis AS, Aplenc R. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 Dec;68(12):e29281. doi: 10.1002/pbc.29281. Epub 2021 Oct 1. PMID: 34596937; PMCID: PMC8717610.

Bolouri H, Ries R, Pardo L, Hylkema T, Zhou W, Smith JL, Leonti A, **Loken M**, Farrar JE, Triche TJ Jr, Meshinchi S. A B-cell developmental gene regulatory network is activated in infant AML. PLoS One. 2021 Nov 18;16(11):e0259197. doi: 10.1371/journal.pone.0259197. PMID: 34793513; PMCID: PMC8601427.

Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, Perkins L, Srivastava S, Call L, Smith J, Leonti A, Ries R, Pardo L, **Loken MR**, Correnti C, Fiorenza S, Turtle CJ, Riddell S, Tarlock K, Meshinchi S. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clin Cancer Res. 2021 Oct 15;27(20):5718-5730. doi: 10.1158/1078-0432.CCR-21-1546. Epub 2021 Aug 11. PMID: 34380639.

Elgarten CW, Wood AC, Li Y, Alonzo TA, **Brodersen LE**, Gerbing RB, Getz KD, Huang YV, **Loken M**, Meshinchi S, Pollard JA, Sung L, Woods WG, Kolb EA, Gamis AS, Aplenc R. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 Oct 1:e29281. doi: 10.1002/pbc.29281. Epub ahead of print. PMID: 34596937.

Getz KD, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi S, Hirsch B, **Loken M, Brodersen LE**, Kahwash S, Choi J, Kolb EA, Gamis A, Aplenc R. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. *Pediatr Blood Cancer.* 2021 Sep 2:e29313. doi: 10.1002/pbc.29313. Epub ahead of print. PMID: 34472213.

Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, Perkins L, Srivastava S, Call L, Smith J, Leonti A, Ries R, Pardo L, **Loken MR**, Correnti C, Fiorenza S, Turtle CJ, Riddell S, Tarlock K, Meshinchi S. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. *Clin Cancer Res.* 2021 Oct 15;27(20):5718-5730. doi: 10.1158/1078-0432.CCR-21-1546. Epub 2021 Aug 11. PMID: 34380639.

Kaeding AJ, Barwe SP, Gopalakrishnapillai A, Ries RE, Alonzo TA, Gerbing RB, Correnti C, **Loken MR, Brodersen LE, Pardo L**, Le QH, Tang T, Leonti AR, Smith JL, Chou CK, **Xu M**, Triche T, Kornblau SM, Kolb EA, Tarlock K, Meshinchi S. Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. *Blood Adv.* 2021 May 11;5(9):2350-2361. doi: 10.1182/bloodadvances.2021004424. PMID: 33938941; PMCID: PMC8114558.

Tarlock K, Lambie A, Wang J, Gerbing RB, Ries RE, **Loken MR, Eidenschink Brodersen L, Pardo L**, Leonti AR, Smith J, Hylkema T, Woods WG, Cooper T, Kolb EA, Gamis AS, Aplenc R, Alonzo T, Meshinchi S. CEBPA bZip Mutations are Associated with Favorable Prognosis in de novo AML: A Report from the Children's Oncology Group. *Blood.* 2021 May 5:blood.2020009652. doi: 10.1182/blood.2020009652. Epub ahead of print. PMID: 33951732.

Brodersen LE, Gerbing RB, **Pardo ML**, Alonzo TA, Paine D, **Fritschle W**, Hsu FC, Pollard JA, Aplenc R, Kahwash SB, Hirsch B, Ramondi S, **Wells D**, Kolb EA, Gamis AS, Meshinchi S, **Loken MR**. Morphologic remission status is limited compared to Δ N flow cytometry: a Children's Oncology Group AAML0531 report. *Blood Adv.* 2020 Oct 27;4(20):5050-5061. doi: 10.1182/bloodadvances.2020002070. PMID: 33080007; PMCID: PMC7594384.

Richard Aplenc, Soheil Meshinchi, Lillian Sung, Todd Alonzo, John Choi, Brian Fisher, Robert Gerbing, Betsy Hirsch, Terzah Horton, Samir Kahwash, John Levine, **Michael Loken, Lisa Brodersen**, Jessica Pollard, Susana Raimondi, Edward Anders Kolb, Alan Gamis. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. *Haematologica.* 2020 Jul; 105(7): 1879–1886. Prepublished online 2020 Feb 6. doi: 10.3324/haematol.2019.220962 PMCID: PMC7327649

Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, **Eidenschink Brodersen L, Pardo L**, Cummings CL, Loeb KR, Le Q, Imren S, Leonti AR, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche TJ Jr, Nguyen C, Meerzaman D, **Loken MR**, Oehler VG, Bolouri H, Meshinchi S. Comprehensive Transcriptome Profiling of Cryptic *CBFA2T3-GLIS2* Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. *Clin Cancer Res.* 2020 Feb 1;26(3):726-737. doi: 10.1158/1078-0432.CCR-19-1800. Epub 2019 Nov 12. PMID: 31719049; PMCID: PMC7002196.

Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries R, **Loken MR**, Pardo L, Hylkema T, Joaquin J, Sarukkai L, Raimondi SC, Hirsch B, Sung L, Aplenc R, Bernstein I, Gamis AS, Meshinchi S, Pollard JA. Functional Properties of *KIT* Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. *Clin Cancer Res.* 2019 Aug 15;25(16):5038-5048. doi: 10.1158/1078-0432.CCR-18-1897. Epub 2019 Jun 10. PMID: 31182436; PMCID: PMC6754181

Pardo LM, Voigt AP, Alonzo TA, Wilson ER, Gerbing RB, Paine DJ, Dai F, Menssen AJ, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, **Wells DA, Brodersen LE, Loken MR**. Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. *Cytometry B Clin Cytom.* 2020 Jan;98(1):52-56. doi: 10.1002/cyto.b.21829. Epub 2019 Jul 11. PMID: 31294507; PMCID: PMC7872511.

Eidenschink Brodersen, Lisa & Hudson, Chad & Alonzo, Todd & Gerbing, Robert & **Pardo, Laura** & Leonti, Amanda & **Singleton, Timothy** & Hsu, Fan-Chi & Lott, Loren & Dai, Fangyan & **Ghiradelli, Keely** & Kolb, E. & Cooper, Todd & Pollard, Jessica & **Loken, Michael** & Aplenc, Richard & Meshinchi, Soheil. (2020). Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group. AAML1031 Protocol. Blood. 136. 39-39. 10.1182/blood-2020-142659.

Eidenschink Brodersen, Lisa & Gerbing, Robert & **Pardo, M.** & Alonzo, Todd & Paine, Dana & **Fritschle, Wayne** & Hsu, Fan-Chi & Pollard, Jessica & Aplenc, Richard & Kahwash, Samir & Hirsch, Betsy & Ramondi, Susana & **Wells, Denise** & Kolb, E. & Gamis, Alan & Meshinchi, Soheil & **Loken, Michael**. (2020). Morphologic remission status is limited compared to Δ N flow cytometry: a Children's Oncology Group AAML0531 report. Blood Advances. 4. 5050-5061. 10.1182/bloodadvances.2020002070.

Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, **Eidenschink Brodersen L, Pardo L**, Cummings CL, Loeb KR, Le Q, Imren S, Leonti AR, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche TJ Jr, Nguyen C, Meerzaman D, Loken MR, Oehler VG, Bolouri H, Meshinchi S. Comprehensive Transcriptome Profiling of Cryptic *CBFA2T3-GLIS2* Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. Clin Cancer Res. 2020 Feb 1;26(3):726-737. doi: 10.1158/1078-0432.CCR-19-1800. Epub 2019 Nov 12. PMID: 31719049; PMCID: PMC7002196.

Pardo, Laura & **Voigt, Andrew** & Alonzo, Todd & Wilson, Elisabeth & Gerbing, Robert & Paine, Dana & Dai, Fangyan & **Menssen, Andrew** & Raimondi, Susana & Hirsch, Betsy & Gamis, Alan & Meshinchi, Soheil & **Wells, Denise** & **Eidenschink Brodersen Lisa** & **Loken, Michael**. (2019). Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Cytometry Part B: Clinical Cytometry. 98. 10.1002/cyto.b.21829.

Lamble, Adam & **Eidenschink Brodersen, Lisa** & Alonzo, Todd & Wang, Jim & Gerbing, Robert & **Pardo, Laura** & Sung, Lillian & Tasian, Sarah & Cooper, Todd & Kolb, E. & Aplenc, Richard & **Loken, Michael** & Meshinchi, Soheil. (2019). Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood. 134. 459-459. 10.1182/blood-2019-124587.

Tarlock, Katherine & **Eidenschink Brodersen, Lisa** & Alonzo, Todd & Wang, Yi-Cheng & Gerbing, Robert & **Pardo, Laura** & Dai, Fangyan & Gamis, Alan & Aplenc, Richard & Pollard, Jessica & **Loken, Michael** & Meshinchi, Soheil. (2019). CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia. Blood. 134. 2699-2699. 10.1182/blood-2019-127100.

Loken, M.R., Brodersen, L.E., Wells, D.A. (2019). Monitoring AML Response Using "Difference from Normal" Flow Cytometry. In: Druley, T. (eds) Minimal Residual Disease Testing. Springer, Cham. https://doi.org/10.1007/978-3-319-94827-0_4

Jacobsohn, David & **Loken, Michael** & Fei, Mingwei & Adams, Alexia & **Eidenschink Brodersen, Lisa** & Logan, Brent & Ahn, Kwang & Shaw, Bronwen & Kletzel, Morris & Olszewski, Marie & Khan, Sana & Meshinchi, Soheil & Keating, Amy & Harris, Andrew & Teira, Pierre & Duerst, Reggie & Margossian, Steven & Martin, Paul & Petrovic, Aleksandra & Pulsipher, Michael. (2018). Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. Biology of Blood and Marrow Transplantation. 24. 10.1016/j.bbmt.2018.06.010.

Lamba JK, **Voigt AP**, Chauhan L, Shin M, Aplenc R, **Eidenschink Brodersen L**, Gamis AS, Meshinchi S, **Loken MR**. CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. *Leuk Lymphoma*. 2018 Sep;59(9):2250-2253. doi: 10.1080/10428194.2017.1421756. Epub 2018 Jan 10. PMID: 29320902; PMCID: PMC7199442.

Voigt AP, Brodersen LE, Alonzo TA, Gerbing RB, **Menssen AJ, Wilson ER**, Kahwash S, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, **Wells DA, Loken MR**. Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. *Haematologica*. 2017 Dec;102(12):2058-2068. doi: 10.3324/haematol.2017.169029. Epub 2017 Sep 7. PMID: 28883080; PMCID: PMC5709105.

Jacobsohn, David & **Loken, Michael** & Fei, Mingwei & Adams, Alexia & **Eidenschink Brodersen, Lisa** & **Fritschle, Wayne** & Logan, Brent & Ahn, Kwang & Olszewski, Marie & Kahn, Sana & Keating, Amy & Harris, Andrew & Teira, Pierre & Margossian, Steven & Duerst, Reggie & Martin, Paul & Boyer, Michael & Nemecek, Eneida & Dvorak, Christopher & Pulsipher, Michael. (2017). Minimal residual disease (MRD) pre- and post- HCT for children with AML is highly predictive of event-free survival: a pediatric blood and marrow transplant consortium study. 10.1038/bmt.2017.131

Todd M Cooper, Rhonda E. Ries, Todd A Alonzo, Robert B Gerbing, **Michael R. Loken, Lisa E. Brodersen**, Susana C. Raimondi, Betsy A Hirsch, Richard Aplenc, Alan S Gamis, Edward A Kolb, Soheil Meshinchi; Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. *Blood* 2017; 130 (Supplement 1): 407. doi: https://doi.org/10.1182/blood.V130.Suppl_1.407.407

Eidenschink Brodersen L, Alonzo TA, **Menssen AJ**, Gerbing RB, **Pardo L, Voigt AP**, Kahwash SB, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, **Loken MR**. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group. *Leukemia*. 2016 Oct;30(10):2077-2080. doi: 10.1038/leu.2016.119. Epub 2016 May 2. PMID: 27133823; PMCID: PMC5136463.

Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, **Loken MR**, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, Meshinchi S. miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. *Pediatr Blood Cancer*. 2016 Dec;63(12):2096-2103. doi: 10.1002/pbc.26157. Epub 2016 Aug 11. PMID: 27511899; PMCID: PMC5497493.

Voigt, Andrew & Eidenschink Brodersen, Lisa & Pardo, Laura & Meshinchi, Soheil & Loken, Michael. (2016). Supplementary Material 3.

Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531. *Blood*, 126(23), pp.1377-1377.

Bennett, John & **Wells, Denise**. (2015). Re: Lee H, et al. An Unusual Case of Myeloperoxidase-Positive Acute Megakaryoblastic Leukemia. *Ann Lab Med* 2015;35:466-8. *Annals of laboratory medicine*. 35. 542-3. 10.3343/alm.2015.35.5.542.

Voigt, Andrew & Eidenschink Brodersen, Lisa & Gerbing, Robert & Menssen, Andrew & Hirsch, Betsy & Raimondi, Susana & Gamis, Alan & Alonzo, Todd & Meshinchi, Soheil & **Loken, Michael**. (2015). Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531. *Blood*. 126. 1377-1377. 10.1182/blood.V126.23.1377.1377.

Loken, Michael & Voigt, Andrew & Gerbing, Robert & Eidenschink Brodersen, Lisa & Menssen, Andrew & Pardo, Laura & Gamis, Alan & Alonzo, Todd & Meshinchi, Soheil. (2015). Hierarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531. Blood. 126. 561-561. 10.1182/blood.V126.23.561.561.

Overholt K, Guinipero TL, Heerema NA, **Loken MR**, Kahwash SB. Promyelocytic Leukemia with No Retinoic Acid Receptor Alpha Abnormality but with RUNX1T1 Insertion to Chromosome 7q: A Classification and Management Dilemma. Case Rep Hematol. 2015;2015:412016. doi: 10.1155/2015/412016. Epub 2015 Aug 17. PMID: 26351594; PMCID: PMC4553303.

Chu, Sung-Chao & Wang, Tso-Fu & Su, Yu-Chieh & Kao, Ruey-Ho & Wu, Yi-Feng & Li, Dian-Kun & Li, Szu-Chin & Li, Chi-Cheng & **Wells, Denise & Loken, Michael.** (2014). Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission. International journal of hematology. 99. 10.1007/s12185-014-1525-y.

Ostronoff F, Othus M, Gerbing RB, **Loken MR**, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014 Oct 9;124(15):2400-7. doi: 10.1182/blood-2014-04-570929. Epub 2014 Aug 21. PMID: 25145343; PMCID: PMC4192751.

Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, **Loken MR**, Razzouk BI. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014 Aug 15;120(16):2482-9. doi: 10.1002/cncr.28674. Epub 2014 Apr 25. PMID: 24771494; PMCID: PMC4126862.

Dong ZMD, Ramakrishnan A, Chauncey TR, **Loken MR, Zehentner B**, et al. (2014) No Adverse Effect of Residual Neoplastic Mast Cells in Systemic Mastocytosis Associated with Acute Myeloid Leukemia with T(8;21)(Q22;Q22); Runx1-Runx1t1 after Bone Marrow Transplantation. Ann Clin Pathol 2(1): 1009.

Ostronoff F, Othus M, Gerbing RB, **Loken MR**, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014 Oct 9;124(15):2400-7. doi: 10.1182/blood-2014-04-570929. Epub 2014 Aug 21. PMID: 25145343; PMCID: PMC4192751.

Loken MR. Residual disease in AML, a target that can move in more than one direction. Cytometry B Clin Cytom. 2014 Jan;86(1):15-7. doi: 10.1002/cyto.b.21140. Epub 2013 Nov 15. PMID: 24243851.

Loken MR, Alonzo TA, **Pardo L**, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012 Aug 23;120(8):1581-8. doi: 10.1182/blood-2012-02-408336. Epub 2012 May 30. PMID: 22649108; PMCID: PMC3429302.

Loken MR, Alonzo TA, **Pardo L**, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012 Aug 23;120(8):1581-8. doi: 10.1182/blood-2012-02-408336. Epub 2012 May 30. PMID: 22649108; PMCID: PMC3429302.

Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. *Blood*. 2012 Aug;120(8):1581-1588. DOI: 10.1182/blood-2012-02-408336.

Hartmann, L. & Stephenson, Christine & Johnson, K. & Chapman, D. & Smading, S. & Burnworth, T. & de Baca, Monica & Wells, Denise & Loken, M. & Zehentner, Barbara. (2012). SNP/CGH Array Can Identify Clonal Evolution in Acute Myelogenous Leukemia. 664-664.

Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA, **Loken MR**, Meshinchi S. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. *J Clin Oncol*. 2010 Jun 10;28(17):2831-8. doi: 10.1200/JCO.2009.27.5693. Epub 2010 Apr 26. PMID: 20421533; PMCID: PMC2903318.

25

Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO, Arceci RJ, Woods WG, **Loken MR.** Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. *Blood*. 2003 May 1;101(9):3398-406. doi: 10.1182/blood-2002-10-3064. Epub 2002 Dec 27. PMID: 12506020.

Wells, Denise & Loken, MR. (1998). More on hematogones. *Laboratory Medicine*. 29. 728-728.

Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO, Arceci RJ, Woods WG, **Loken MR.** Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. *Blood*. 2003 May 1;101(9):3398-406. doi: 10.1182/blood-2002-10-3064. Epub 2002 Dec 27. PMID: 1250602

Sievers EL, Lange BJ, Buckley JD, Smith FO, **Wells DA**, Daigneault-Creech CA, Shults KE, Bernstein ID, **Loken MR.** Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. *J Natl Cancer Inst*. 1996 Oct 16;88(20):1483-8. doi: 10.1093/jnci/88.20.1483. PMID: 8841024.

Sievers EL, **Loken MR.** Detection of minimal residual disease in acute myelogenous leukemia. *J Pediatr Hematol Oncol*. 1995 May;17(2):123-33. doi: 10.1097/00043426-199505000-00005. PMID: 7749761.

Wells, Denise & Loken, Michael & Shulman, Howard & Myerson, David. (1994). Multi-dimensional flow cytometric antigenic comparison of bone marrow from normal, AML and MDS patients. *Leukemia Research*. 18. 5. 10.1016/0145-2126(94)90137-6.

Terstappen LW, Safford M, Könemann S, **Loken MR**, Zurlutter K, Büchner T, Hiddemann W, Wörmann B. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. *Leukemia*. 1992 Jan;6(1):70-80. PMID: 1540262.

Terstappen LW, **Loken MR.** Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. *Anal Cell Pathol*. 1990 Jul;2(4):229-40. PMID: 1703434.

Terstappen LWMM, **Loken MR.** Multi-dimensional flow cytometric characterization of myeloid maturation in normal bone marrow and acute myeloid leukemia. i. In: Burger G, Oberholzer M, Vooijs GP (eds). *Advances in Analytical Cellular Pathology*. Excerpta Medica: Amsterdam, 1990, pp 209.

MPAL

Huang, J.J., Appelbaum, J.S., Russell, K., Shaw, C., **Eckel, A.M.**, Chen, X., Vyas, R.D., Hendrie, P.C., Halpern, A.B., Mawad, R. and Cassaday, R.D., 2023. Treatment Outcomes for Adults with Mixed Phenotypic Acute Leukemia: A Large Single-Center Retrospective Study. *Blood*, 142, p.2838.

AML RAM

Andrew Menssen, Jacqueline Cook, Todd Alonzo, Robert Gerbing, **Maria Pardo, Fan-Chi Hsu, Loren Lott, Fangyan Dai, Amenech Ashango, Thanh Thanh Dinh**, Todd Cooper, Jessica Pollard, Katherine Tarlock, Lisa Brodersen, **Michael Loken**, Soheil Meshinchi, **Chad Hudson**. "Analysis of 3346 patients from the combined Children's Oncology Group AML studies further characterizes RAM immunophenotype AML and reveals other associated phenotypes and genetic drivers." *Blood* 146 (2025): 337.

Maya Ball-Burack, Andrew Menssen, Lisa Eidenschink Brodersen, **Arun Nalla, Michael Loken, Laura Pardo**, Ann Dahlberg, **Chad Hudson**, Soheil Meshinchi, Katherine Tarlock. A Case of Blinatumomab Efficacy in RAM Immunophenotype/CBFA2T3::GLIS2 Fusion AML. *Pediatr Blood Cancer*. 2025;72(12):e32035. doi:10.1002/pbc.32035

Conces M, Abu-Arja R, Reed S, Rangarajan HG, Guinipero TL, **Loken MR, Brodersen LE**, Kahwash SB. Acute Myeloid Leukemia with RAM Immunophenotype: A Pediatric Case with Unusual Morphologic Features. *Hematol Rep*. 2017 Jun 14;9(2):7057. doi: 10.4081/hr.2017.7057. PMID: 28670435; PMCID: PMC5477472.

AML Down Syndrome

Jason N Berman, Anupam Verma, Shelton A. Viola, Todd Alonzo, Yi-Cheng Wang, Lisa Eidenschink Brodersen, **Michael R Loken**, Amy K. Beckman, Betsy A Hirsch, Susana Raimondi, Karen M. Chisholm, Xiaotu Ma, Rhonda E. Ries, Soheil Meshinchi, Alan S Gamis, Reuven J Schore, Jeffrey W. Taub, E Anders Kolb, Todd M Cooper, Johann K. Hitzler, Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual Disease. *Blood Advances*. Published online October 22, 2025. doi:https://doi.org/10.1182/bloodadvances.2025017837.

Hsu FC, Hudson C, Wilson ER, Pardo LM, Singleton TP, Xu D, Zehentner BK, Hitzler J, Berman J, **Wells DA, Loken MR, Brodersen LE**. The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease. *Cytometry B Clin Cytom*. 2023 Jul;104(4):311-318. doi: 10.1002/cyto.b.22118. Epub 2023 Apr 4. PMID: 37015883.

Hsu FC, Hudson C, Wilson ER, Pardo LM, Singleton TP, Xu D, Zehentner BK, Hitzler J, Berman J, **Wells DA, Loken MR, Brodersen LE** (2023) The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease. *Cytometry B Clinical Cytometry*. doi: 10.1002/cyto.b.22118.

Johann K. Hitzler, MD , Todd A. Alonzo, PhD , Robert Gerbing, MS , Jim Wang, MS , Amy Beckman, MD , Betsy Hirsch, PhD , Susana C. Raimondi, PhD , Karen M Chisholm, MD, PhD, Shelton A. Viola, MD , Anupam Verma, MD , Lisa Eidenschink Brodersen, PhD , **Michael R. Loken, PhD** , Jeffrey W. Taub, MD , Alan S Gamis, MD, MPH , E. Anders Kolb, MD , Todd M Cooper, DO and Jason N. Berman, MD. 2949 Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group; Program: Oral and Poster Abstracts Session: 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster II Hematology Disease Topics & Pathways: Combination therapy, Pediatric, Treatment Considerations, Adverse Events, Study Population, Human, Measurable Residual Disease ASH 2024

Rosenzweig J, Pillai PM, Prockop S, Benayed R, **Eidenschink Brodersen L**, Najfeld V, Loken MR, Zhang Y, Shukla N. Acute myeloid leukemia with an *MN1-ETV6* fusion in a young child with Down syndrome. Cold Spring Harb Mol Case Stud. 2022 Apr 28;8(3):a006167. doi: 10.1101/mcs.a006167. PMID: 35483876; PMCID: PMC9059786

Hitzler J, Alonzo T, Gerbing R, Beckman A, Hirsch B, Raimondi S, Chisholm K, Viola S, **Brodersen L, Loken M**, Tong S, Druley T, O'Brien M, Hijiya N, Heerema-McKenney A, Wang YC, Schore R, Taub J, Gamis A, Kolb EA, Berman JN. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021 Dec 9;138(23):2337-2346. doi: 10.1182/blood.2021012206. PMID: 34320162; PMCID: PMC8662073.

Elisabeth R Wilson, **Lisa Eidenschink Brodersen, Barbara Katharina Zehentner, Andrew J. Menssen, Andrew P. Voigt, Laura Pardo, Denise A. Wells**, Johann Hitzler, Jason N. Berman, Todd A. Alonzo, Samir B. Kahwash, Soheil Meshinchi, **Michael R. Loken**; Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration. Blood 2016; 128 (22): 1687. doi: <https://doi.org/10.1182/blood.V128.22.1687.1687>

AML Gemtuzumab Ozogamicin (Mylotarg™) Treatment

John F. DiPersio MD, PhD, Guenther Koehne M.D., PhD, Nirali N. Shah MD, HSc, Alain Mina MD, Lea Bernard MD, Hyung C. Suh MD, PhD, Divya Koura MD, Miguel Angel Perales MD, Roni Tamari MD, Muhammad Umair Mushtaq MD, Joseph E. Maakaron MD, Vanessa E Kennedy MD, Lori S. Muffly MD, Sagar S. Patel MD, **Michael Loken PhD, Chad Hudson MD**, PhD, Darren Stanizzi BA, Melissa Lee-Sundlov PhD, Sanjana Thosar PhD, Sharon L. Hyzy MS, Brenda Cooper MD. "A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)." *Transplantation and Cellular Therapy* 31, no. 2 (2025): S61-S62.

Jessica A. Pollard, MD; Erin Guest, MD; Todd A. Alonzo, PhD; Robert B. Gerbing, MS; **Mike R. Loken, PhD; Lisa Eidenschink Brodersen, PhD**; E. Anders Kolb, MD; Richard Aplenc, MD, PhD; Soheil Meshinchi, MD, PhD; Susana C. Raimondi, PhD; Betsy Hirsch, PhD; and Alan S. Gamis, MD, 2023. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results from the Phase III Children's Oncology Group Trial AAML0531, Journal of Clinical Oncology, Volume 39, Issue 29, 3149-3160.

Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Robert Gerbing, MS, Matthew A. Kutny, MD, Betsy Hirsch, PhD, Gordana Raca, MD PhD, Kasey Leger, MD MSc, Jennifer J. Wilkes, MD MSCE, Aman Wadhwa, MD, Zachary Graff, MD, Reena Pabari, MD, MSc, FRCPC, Samir Kahwash, MD, Karen M Chisholm, MD PhD, Joseph Chewing, MD, John T. Horan, MD, Richard Aplenc, Katherine Tarlock, MD, Sarah Menig, PharmD, BCOP, Olga Militano, PharmD, Bonnie Ky, MD, **Chad A. Hudson, MD PhD**, Lisa Eidenschink Brodersen, PhD, **Michael R. Loken, PhD**, Soheil Meshinchi, MD PhD, Anders Kolb, MD, Todd M Cooper, DO.; A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO-a Report from the Children's Oncology Group. Blood, 144, p.967.

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, **Michael R. Loken**, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne, Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT), Blood, Volume 142, Supplement 1, 2023, Page 483, ISSN 0006-4971

Koehne, Guenther; Tomlinson, Benjamin; Suh, Hyung; Koura, Divya; Cho, Christina³; Bambace, Nadia M; Bernard, Léa⁶; Shah, Nirali N; Walter, Roland; DiPersio, Joh⁹; Perales, Miguel-Angel; **Loken, Michael R**; Breitschwerdt, Kyle; Nath, Sritama; Raffel, Glen; Cooper, Brenda W. P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS. HemaSphere 7(S3):p e24418bc, August 2023.

Pollard JA, Guest E, Alonzo TA, Gerbing RB, **Loken MR, Brodersen LE**, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis AS. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric *KMT2A*-Rearranged AML: Results from the Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2021 Oct 1;39(28):3149-3160. doi: 10.1200/JCO.20.03048. Epub 2021 May 28. PMID: 34048275; PMCID: PMC8478392.

Gbadamosi MO, Shastri VM, Hylkema T, Papageorgiou I, Pardo L, Cogle CR, Doty A, **Loken MR**, Meshinchi S, Lamba JK. Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms. Future Oncol. 2021 Jan;17(3):263-277. doi: 10.2217/fon-2020-0746. Epub 2020 Dec 24. PMID: 33356566.

Papageorgiou, Ioannis & **Loken, Michael & Eidenschink Brodersen, Lisa** & Gbadamosi, Mohammed & Uy, Geoffrey & Meshinchi, Soheil & Lamba, Jatinder. (2019). CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. Leukemia & Lymphoma. 60. 1-4. 10.1080/10428194.2019.1569232.

DiPersio, J.F., Koehne, G., Shah, N.N., Bernard, L., Suh, H.C., Koura, D., Perales, M.A., Tamari, R., Mushtaq, M.U., Maakaron, J.E. and **Loken, M.R.**, 2024. A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML). Blood, 144, p.2873.

Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries R, **Loken MR, Pardo L**, Hylkema T, Joaquin J, Sarukkai L, Raimondi SC, Hirsch B, Sung L, Aplenc R, Bernstein I, Gamis AS, Meshinchi S, Pollard JA. Functional Properties of *KIT* Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. Clin Cancer Res. 2019 Aug 15;25(16):5038-5048. doi: 10.1158/1078-0432.CCR-18-1897. Epub 2019 Jun 10. PMID: 31182436; PMCID: PMC6754181

Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, **Loken MR**, Pollard J, Aplenc R, Raimondi S, Hirsch BA, Bernstein ID, Gamis AS, Meshinchi S, Lamba JK. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. Blood Cancer J. 2019 May 21;9(6):51. doi: 10.1038/s41408-019-0211-y. PMID: 31113932; PMCID: PMC6529443.

Pardo, Laura & Eidenschink Brodersen, Lisa & Lamba, Jatinder & Alonzo, Todd & Wang, Yi-Cheng & Paine, Dana & Gamis, Alan & Kolb, E. & Pollard, Jessica & Cooper, Todd & Aplenc, Richard & Meshinchi, Soheil & Loken, Michael. (2018). Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531. Blood. 132. 1490-1490. 10.1182/blood-2018-99-115053.

Lamba JK, Chauhan L, Shin M, **Loken MR**, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report from Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23. PMID: 28644774; PMCID: PMC5549451.

Pollard, Jessica A.; **Loken, Michael**; Gerbing, Robert B.; Raimondi, Susana C.; Hirsch, Betsy A.; Aplenc, Richard; Bernstein, Irwin D.; Gamis, Alan S.; Alonzo, Todd A.; Meshinchi, Soheil. CD33 expression and its association with gemtuzumab ozogamicin response : Results from the randomized phase III children's oncology group trial AAML0531. In: Journal of Clinical Oncology, Vol. 34, No. 7, 01.03.2016, p. 747-755.

Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, **Loken MR**, Gamis AS, Meshinchi S. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 Apr 15;22(8):1951-7. doi: 10.1158/1078-0432.CCR-15-1349. Epub 2015 Dec 7. PMID: 26644412; PMCID: PMC4834220.

Pollard JA, **Loken M**, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Expression and Its Association with Gemtuzumab Ozogamicin Response: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2016 Mar 1;34(7):747-55. doi: 10.1200/JCO.2015.62.6846. Epub 2016 Jan 19. PMID: 26786921; PMCID: PMC4872025.

Pollard, J., Alonzo, T.A., Gerbing, R.B., Raimondi, S.C., Hirsch, B.A., Sung, L., Aplenc, R., Guest, E.M., Bernstein, I.D., **Loken, M.R.** and Meshinchi, S., 2015. Treatment of 11q23/MLL+ AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531. Blood, 126(23), pp.799-799.

Jessica Pollard, Todd A. Alonzo, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Lillian Sung, Richard Aplenc, Erin M. Guest, Irwin D. Bernstein, **Michael R. Loken**, Soheil Meshinchi, Alan S. Gamis; Treatment of 11q23/MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531. Blood 2015; 126 (23): 799. doi: <https://doi.org/10.1182/blood.V126.23.799.799>

Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, **Loken MR**, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, Meshinchi S, Lamba JK. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013 Mar 15;19(6):1620-7. doi: 10.1158/1078-0432.CCR-12-3115. Epub 2013 Feb 26. PMID: 23444229; PMCID: PMC3602123.

Pollard JA, Alonzo TA, **Loken M**, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB, Gamis A, Meshinchi S. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012 Apr 19;119(16):3705-11. doi: 10.1182/blood-2011-12-398370. Epub 2012 Feb 29. PMID: 22378848; PMCID: PMC3335378.

Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, **Loken MR**, van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 1;19(13):3244-54. doi: 10.1200/JCO.2001.19.13.3244. PMID: 11432892. 22

Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Muntea M, **Loken MR**, Van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group. Antibody-targeted chemotherapy of old patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002 Sep;16(9):1627-36. doi: 10.1038/sj.leu.2402677. PMID: 12200674.

Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, **Loken MR**, van Dongen JJ, Bernstein ID, Appelbaum FR. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 1;104(7):1442-52. doi: 10.1002/cncr.21326. PMID: 16116598.

Walter RB, Gooley TA, van der Velden VH, **Loken MR**, van Dongen JJ, Flowers DA, Bernstein ID, Appelbaum FR. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007 May 15;109(10):4168-70. doi: 10.1182/blood-2006-09-047399. Epub 2007 Jan 16. PMID: 17227830; PMCID: PMC1885511.

CLL

Dong Q, Wang Y, Xiu Y, Sakr H, **Burnworth B, Xu D**, O'Brien T, Burke J, Hu S, Zeng G, Zhao C. Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma. Br J Haematol. 2023 Mar;200(5):660-664. doi: 10.1111/bjh.18565. Epub 2022 Nov 14. PMID: 36375473; PMCID: PMC10162861.

Sorrer ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, **Loken MR**, Al-Ali H, Blume KG, Storb R, Maloney DG. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 1;23(16):3819-29. doi: 10.1200/JCO.2005.04.569. Epub 2005 Apr 4. PMID: 15809448.

CML

Brivio E, Pennesi E, Willemse ME, Huitema ADR, Jiang Y, van Tinteren HDR, van der Velden VHJ, Beverloo BH, den Boer ML, Rammeloo LAJ, **Hudson C**, Heerema N, Kowalski K, Zhao H, Kuttschreuter L, Bautista Sirvent FJ, Bukowinski A, Rizzari C, Pollard J, Murillo-Sanjuán L, Kutny M, Zarnegar-Lumley S, Redell M, Cooper S, Bertrand Y, Petit A, Krystal J, Metzler M, Lancaster D, Bourquin JP, Motwani J, van der Sluis IM, Locatelli F, Roth ME, Hijiya N, Zwaan CM. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. J Clin Oncol. 2024 Mar 1;42(7):821-831. doi: 10.1200/JCO.23.00897. Epub 2023 Nov 30. PMID: 38033284; PMCID: PMC10906575.

Brivio, E., Pennesi, E., Willemse, M., Jiang, Y., van der Velden, V., Beverloo, B., **Hudson, C.**, Kuttschreuter, L., van der Sluis, I., Brethon, B. and Bautista, F., 2023. P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA. HemaSphere, 7(Suppl).

Edoardo Pennesi, Erica Brivio, Marieke E Willemse, Yilin Jiang, Vincent HJ van der Velden, H Berna Beverloo, **Chad Hudson**, Nyla A Heerema, Luke Kuttschreuter, Jamie Frediani, Susan Spiller, Sandeep Batra, Michele Redell, Nicoletta Bertorello, Franco Locatelli, Inge M van der Sluis, Michael Roth, Nobuko Hijiya, C Michel Zwaan. Preliminary results from the first-in-child phase II trial (ITCC-054/COGAAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML). DOI: 10.1200/JCO.2023.41.16_suppl.10017 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 10017-10017.

Brivio, E., Pennesi, E., Willemse, M.E., Huitema, A.D., Jiang, Y., van Tinteren, H.D., van der Velden, V.H., Beverloo, B.H., den Boer, M.L., Rammeloo, L.A. and **Hudson, C.**, Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, p.JCO2300897.

Freedman JL, Desai AV, Bailey LC, Aplenc R, **Burnworth B, Zehentner BK**, Teachey DT, Wertheim G. Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. Pediatr Blood Cancer. 2016 Jan;63(1):156-9. doi: 10.1002/pbc.25694. Epub 2015 Aug 14. PMID: 26274939.

MPL

Burnworth, B. & Bennington, R. & Fritschle, W. & Nguyen, P. & Verkamp, S. & Wang, Z. & Wells, Denise & Loken, M. & Zehentner, Barbara. (2014). Detection of CALR Exon9 and MPL Mutations in Multiple Lineages of Myeloproliferative Neoplasms: Combining Cell Sorting with Molecular Testing. November 2014, The Journal of Molecular Diagnostics: JMD Conference: Annual Meeting of the Association-for-Molecular-Pathology (AMP), Volume: 16, 716-716.

Zehentner BK, Loken MR, Wells DA. JAK2V617F mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders. Am J Hematol. 2006 Oct;81(10):806-7. doi: 10.1002/ajh.20663. PMID: 16886215.

Plasma Cells

Zehentner BK, de Baca ME, Wells DA, Loken MR. Intraclonal heterogeneity in concomitant monoclonal lymphocyte and plasma cell populations: combining flow cytometric cell sorting with molecular monoclonality profiling. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):214-7. doi: 10.1016/j.clml.2013.02.004. Epub 2013 Mar 13. PMID: 23490988.

Zehentner BK, Hartmann L, Johnson KR, Stephenson CF, Chapman DB, de Baca ME, Wells DA, Loken MR, Tirtorahardjo B, Gunn SR, Lim L. Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations. Am J Clin Pathol. 2012 Oct;138(4):579-89. doi: 10.1309/AJCPKW31BAIMVGST. PMID: 23010713.

Hartmann, L. & Lim, L. & Johnson, K. & Stephenson, Christine & Chapman, D. & de Baca, Monica & Wells, Denise & Loken, M. & Tirtorahardjo, B. & Gunn, S. & Zehentner, Barbara. Array Comparative Genomic Hybridization (aCGH) post Plasma Cell Enrichment Increases Detection of Genomic Aberrations in Plasma Cell Neoplasia. November 2012, The Journal of Molecular Diagnostics: JMD Conference: Annual Meeting of the Association-for-Molecular-Pathology, Volume: 14, 663-663.

Zehentner BK, Hartmann L, Johnson KR, Stephenson CF, Chapman DB, de Baca ME, Wells DA, Loken MR, Tirtorahardjo B, Gunn SR, Lim L. Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations. Am J Clin Pathol. 2012 Oct;138(4):579-89. doi: 10.1309/AJCPKW31BAIMVGST. PMID: 23010713.

Zehentner BK, Cutler JA, Fritschle WK, Bennington RK, Wentzel C, Smading SR, Jeffery EW, Wells DA, Loken MR. A minority of concurrent monoclonal lymphocytes and plasmacytic cells sharing light chains are genetically related in putative lymphoplasmacytic lymphoma. Leuk Res. 2011 Dec;35(12):1597-604. doi: 10.1016/j.leukres.2011.06.012. Epub 2011 Jul 14. PMID: 21752465.

McSweeney, P & Wells, Denise & Shults, Keith & Nash, R & Bensinger, wm & Buckner, C & Loken, M. (1996). Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. Blood. 88. 622-32. 10.1182/blood.V88.2.622.bloodjournal882622.

Loken MR, Leibson PJ, Schreiber H. Heritable and non-heritable variations in the phenotype of myeloma cells as detected by a fluorescence-activated cell sorter. J Histochem Cytochem. 1979 Dec;27(12):1647-8. doi: 10.1177/27.12.521620. PMID: 521620.

Leibson PJ, Loken MR, Panem S, Schreiber H. Clonal evolution of myeloma cells leads to quantitative changes in immunoglobulin secretion and surface antigen expression. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2937-41. doi: 10.1073/pnas.76.6.2937. PMID: 288078; PMCID: PMC383725.

BMT

Foster JH, Hawkins DS, Loken MR, Wells DA, Thomson B. Minimal residual disease detected prior to hematopoietic cell transplantation. Pediatr Blood Cancer. 2011 Jul 15;57(1):163-5. doi: 10.1002/pbc.23079. Epub 2011 Mar 2. PMID: 21370437.

Burroughs LM, Storb R, Leisenring WM, Pulsipher MA, Loken MR, Torgerson TR, Ochs HD, Woolfrey AE. Intensive post grafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant. 2007 Oct;40(7):633-42. doi: 10.1038/sj.bmt.1705778. Epub 2007 Jul 30. PMID: 17660844.

Sala-Torra O, Hanna C, Loken MR, Flowers ME, Maris M, Ladne PA, Mason JR, Senitzer D, Rodriguez R, Forman SJ, Deeg HJ, Radich JP. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 May;12(5):511-7. doi: 10.1016/j.bbmt.2006.01.006. PMID: 16635786.

Mielcarek M, Bryant E, Loken M, Zaucha JM, Torok-Storb B, Storb R. Long-term engraftment and clonal dominance of donor derived del(20q) hematopoietic cells after allogeneic stem cell transplantation. Blood. 2006 Feb 15;107(4):1732-3. doi: 10.1182/blood-2005-09-3781. PMID: 16461763. **Donor tumor**

Olga Sala-Torra, Colleen Hanna, Michael R. Loken, Mary E.D. Flowers, Michael Maris, Paula A. Ladne, James R. Mason, David Senitzer, Roberto Rodriguez, Stephen J. Forman, H. Joachim Deeg, Jerald P. Radich, Evidence of Donor-Derived Hematologic Malignancies after Hematopoietic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, Volume 12, Issue 5, 2006, Pages 511-517, ISSN 1083-8791, <https://doi.org/10.1016/j.bbmt.2006.01.006>. **Donor tumor post-transplant, 12 ca**

Wang L, **Wells DA**, Deeg HJ, **Loken MR**. Flow cytometric detection of nonneoplastic antigenic polymorphisms of donor origin after allogeneic marrow transplant: a report of two cases. Am J Clin Pathol. 2004 Jul;122(1):135-40. doi: 10.1309/UAR9-WVFH-4AGH-M5ME. PMID: 15272542.

Shulman HM, **Wells D**, Gooley T, Myerson D, Bryant E, **Loken MR**. The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry. Am J Clin Pathol. 1999 Oct;112(4):513-23. doi: 10.1093/ajcp/112.4.513. PMID: 10510674.

Wells DA, Sale GE, Shulman HM, et al. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. American Journal of Clinical Pathology. 1998 Jul;110(1):84-94. DOI: 10.1093/ajcp/110.1.84.

Lymphoma

Mao ZJ, Surowiecka M, Linden MA, **Singleton TP**. Abnormal immunophenotype of the T-cell-receptor beta Chain in follicular-helper T cells of angioimmunoblastic T-cell lymphoma. Cytometry B Clin Cytom. 2015 May-Jun;88(3):190-3. doi: 10.1002/cyto.b.21229. Epub 2015 Apr 7. PMID: 25619965.

Xu, Dongbin & Gu, Simon & Hammock, Kelle & Burnworth, Tina & Zehentner, Barbara. (2016). A Case of “Triple-Hit” Lymphoma Diagnosed by Integrated Cytogenetic Approaches: FISH, Karyotyping and Microarray. Cancer Genetics. 209. 241. 10.1016/j.cancergen.2016.05.039.

Burnworth B, Wang Z, Singleton TP, Bennington A, Fritschle W, Bennington R, Brodersen LE, Wells DA, Loken MR, Zehentner BK. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Leuk Res. 2016 Dec;51:41-48. doi: 10.1016/j.leukres.2016.10.008. Epub 2016 Oct 18. PMID: 27890075.

Burnworth, B., Wang, Z., Fritschle, W., Bennington, R., Bennington, A., Wentzel, C., Verkamp, S., Nguyen, P., Ghirardelli, K., Brodersen, L.E. and Wells, D.A., 2015, November. Flow Cytometric Cell Sorting of Plasma and Lymphoid Cell Clones prior to MYD88 L265P and CXCR4 Mutation Detection Improves Sensitivity and Specificity for WM/LPL Diagnosis. In *JOURNAL OF MOLECULAR DIAGNOSTICS* (Vol. 17, No. 6, pp. 766-766). 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA: ELSEVIER SCIENCE INC.

Loken, M.R. & Rowley, S. & McSweeney, P. & Wells, Denise. (2001). Quantification of lymphoma in CD34+ enriched stem cell harvests: Evidence for nonrandom, nonspecific contamination. Cancer Research, Therapy and Control. 11. 33-39.

Loken MR, Rowley S, McSweeney P, Wells, DA: Quantification of Lymphoma in CD34+ enriched stem cell harvests: Evidence for non-random, non-specific contamination. Cancer Research Therapy and Control, 2000, Vol 1, 1-7.

Stelzer GT, Shults KE, Wormsley SB, **Loken MR**. Detection of occult lymphoma cells in bone marrow aspirates by multi-dimensional flow cytometry. Prog Clin Biol Res. 1992;377:629-35. PMID: 1438444.

Cytogenetics/FISH/SNP Microarray

Hartmann, L., Cook, J., Lott, L., Perry, J., Wells, D., Loken, M., Menssen, A. and Xu, D., 2024. 18. Tumor specific cell sorting improves sensitivity of FISH: Implications for patients with hematologic malignancies. Cancer Genetics, 286, p.S6. Poster presentation at CGC 2024 Annual Meeting (LH)

Hartmann L, Stephenson CF, Verkamp SR, Johnson KR, Burnworth B, Hammock K, Brodersen LE, de Baca ME, Wells DA, Loken MR, Zehentner BK. Detection of clonal evolution in hematopoietic malignancies by combining comparative genomic hybridization and single nucleotide polymorphism arrays. Clin Chem. 2014 Dec;60(12):1558-68. doi: 10.1373/clinchem.2014.227785. Epub 2014 Oct 15. PMID: 25320376.

Combining Flow Cytometry and Molecular Biology

Kaur M, Blair J, Devkota B, Fortunato S, Clark D, Lawrence A, Kim J, Do W, Semeo B, Katz O, Mehta D, Yamamoto N, Schindler E, Al Rawi Z, Wallace N, Wilde JJ, McCallum J, Liu J, **Xu D**, Jackson M, Rentas S, Tayoun AA, Zhe Z, Abdul-Rahman O, Allen B, Angula MA, Anyane-Yeboah K, Argente J, Arn PH, Armstrong L, Basel-Salmon L, Baynam G, Bird LM, Bruegger D, Ch'ng GS, Chitayat D, Clark R, Cox GF, Dave U, DeBaere E, Field M, Graham JM Jr, Gripp KW, Greenstein R, Gupta N, Heidenreich R, Hoffman J, Hopkin RJ, Jones KL, Jones MC, Kariminejad A, Kogan J, Lace B, Leroy J, Lynch SA, McDonald M, Meagher K, Mendelsohn N, Micule I, Moeschler J, Nampoothiri S, Ohashi K, Powell CM, Ramanathan S, Raskin S, Roeder E, Rio M, Rope AF, Sangha K, Scheuerle AE, Schneider A, Shalev S, Siu V, Smith R, Stevens C, Tkemaladze T, Toimie J, Toriello H, Turner A, Wheeler PG, White SM, Young T, Loomes KM, Pipan M, Harrington AT, Zackai E, Rajagopalan R, Conlin L, Deardorff MA, McEldrew D, Pie J, Ramos F, Musio A, Kline AD, Izumi K, Raible SE, Krantz ID. Genomic analyses in Cornelia de Lange Syndrome and related diagnoses: Novel candidate genes, genotype-phenotype correlations and common mechanisms. Am J Med Genet A. 2023 Aug;191(8):2113-2131. doi: 10.1002/ajmg.a.63247. Epub 2023 Jun 28. PMID: 37377026; PMCID: PMC10524367.

Zehentner, Barbara & de Baca, Monica & Wells, Denise & Loken, Michael. (2013). Intraconal Heterogeneity in Concomitant Monoclonal Lymphocyte and Plasma Cell Populations: Combining Flow Cytometric Cell Sorting with Molecular Monoclonality Profiling. Clinical lymphoma, myeloma & leukemia. 13. 10.1016/j.clml.2013.02.004.

Zehentner BK, Fritschle W, Stelzer T, Ghirardelli KM, Hunter K, Wentzel C, Bennington R, Hansen CL, Myerson D, **Kalnoski M, Wells DA, Loken MR.** Minimal disease detection and confirmation in hematologic malignancies: combining cell sorting with clonality profiling. Clin Chem. 2006 Mar;52(3):430-7. doi: 10.1373/clinchem.2005.061259. Epub 2006 Jan 12. PMID: 16410340.

Molecular Genetics

Eckel A, Olson N, Hartmann L, Cheng H, Xu D. Patient with blast phase multilineage (B and myeloid) neoplasm with FGFR1 rearrangement and RUNX1 mutation. European Association for Haematopathology (EAHP) 2024.

Amenech Ashango, Nigar Zaidi, **Chad Hudson MD PhD, Denise Wells MD,** William Palko MD, **Ashley Eckel MD PhD.** Myeloid neoplasm with RUNX1 mutation demonstrating an associated plasmacytoid dendritic cell proliferation. International Clinical Cytometry Society (ICCS) 2024. Oral presentation at 2024 ICCS Meeting (AE)

Zehentner, B.K. (2019). Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies. In: Druley, T. (eds) Minimal Residual Disease Testing. Springer, Cham. https://doi.org/10.1007/978-3-319-94827-0_3

Burnworth B, Wang Z, Singleton TP, Bennington A, Fritschle W, Bennington R, Brodersen LE, Wells DA, Loken MR, Zehentner BK. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Leuk Res. 2016 Dec;51:41-48. doi: 10.1016/j.leukres.2016.10.008. Epub 2016 Oct 18. PMID: 27890075.

Burnworth, Bettina & Bennington, Richard & Fritschle, Wayne & Nguyen, Phung & Verkamp, Stephanie & Angela, Bennington & Wentzel, Collette & Broderson, Lisa & Loken, Michael & Wells, Denise & Zehentner, Barbara. (2014). Lineage-Specific Distribution of CALR EXON 9, JAK2V617F, MPLW515L/K, NPM1 and FLT3 Mutations in Myeloid Disorders. Blood. 124. 5573-5573. 10.1182/blood.V124.21.5573.5573.

Smith AG, Fan W, Regen L, Warnock S, Sprague M, Williams R, Nisperos B, Zhao LP, **Loken MR**, Hansen JA, Pereira S. Somatic mutations in the HLA genes of patients with hematological malignancy. Tissue Antigens. 2012 May;79(5):359-66. doi: 10.1111/j.1399-0039.2012.01868.x. PMID: 22489945.

Cutler JA, Wells DA, van de Loosdrecht AA, **de Baca ME, Kalnoski MH, Zehentner BK, Eidenschink L, Ghirardelli KM, Biggerstaff JS, Loken MR.** Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias. Cytometry B Clin Cytom. 2011 May;80(3):150-7. doi: 10.1002/cyto.b.20582. Epub 2010 Dec 23. PMID: 21520402.

Zehentner BK, Loken MR, Wells DA. JAK2V617F mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders. Am J Hematol. 2006 Oct;81(10):806-7. doi: 10.1002/ajh.20663. PMID: 16886215.

Zehentner, Barbara & Fritschle, W & Ghirardelli, KM & Stelzer, T & Wentzel, C & Hunter, K & Bennington, R & Kalnoski, M & Wells, Denise & Loken, MR. (2005). Combining cell sorting with clonal profiling: Confirmation of minimal disease for monitoring hematopoietic malignancies. Annual Meeting of the American-Society-for-Clinical-Pathology, Volume: 124, 631-632.

Zehentner BK, Fritschle W, Stelzer T, Ghirardelli KM, Hunter K, Wentzel C, Bennington R, Hansen CL, Myerson D, Kalnoski M, Wells DA, Loken MR. Minimal disease detection and confirmation in hematologic malignancies: combining cell sorting with clonality profiling. Clin Chem. 2006 Mar;52(3):430-7. doi: 10.1373/clinchem.2005.061259. Epub 2006 Jan 12. PMID: 16410340.

Basic Research

Windisch, R., Soliman, S., Hoffmann, A., Chen-Wichmann, L., Danese, A., Vosberg, S., Bravo, J., Lutz, S., Kellner, C., Fischer, A., Gebhard, C., Redondo Monte, E., **Hartmann, L.**, Schneider, S., Beier, F., Strobl, C. D., Weigert, O., Peipp, M., Schündeln, M., Stricker, S. H., ... Wichmann, C. (2024). Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes. Proceedings of the National Academy of Sciences of the United States of America, 121(25), e2312499121. <https://doi.org/10.1073/pnas.2312499121>

Larsen, S.E., Erasmus, J.H., Reese, V.A., Pecor, T., Archer, J., Kandahar, A., **Hsu, F.C.**, Nicholes, K., Reed, S.G., Baldwin, S.L. and Coler, R.N., 2023. An RNA-based vaccine platform for use against mycobacterium tuberculosis. Vaccines, 11(1), p.130.

Eidenschink Brodersen, Lisa & Dizerega, Gere & Rodgers, Kathy & Bartlett, Mark & Wells, Denise & Loken, Michael. (2012). Basal Levels of CD34 Positive Cells in Peripheral Blood Differ Between Individuals and are Stable for 18 Months. Cytometry. Part B, Clinical Cytometry. 82. 18-25. 10.1002/cyto.b.20611.

Larsen, S.E., Erasmus, J.H., Reese, V.A., Pecor, T., Archer, J., Kandahar, A., **Hsu, F.C.**, Nicholes, K., Reed, S.G., Baldwin, S.L. and Coler, R.N., 2023. An RNA-based vaccine platform for use against mycobacterium tuberculosis. Vaccines, 11(1), p.130.

Sonnenfeld G, Measel J, **Loken MR**, Degioanni J, Follini S, Galvagno A, Montalbini M. Effects of isolation on interferon production and hematological and immunological parameters. J Interferon Res. 1992 Apr;12(2):75-81. doi: 10.1089/jir.1992.12.75. PMID: 1578189.

Willard-Gallo KE, Houck DW, **Loken MR**. Analysis of human lymphocyte protein expression. I. Identification of subpopulation markers by two-dimensional polyacrylamide gel electrophoresis. Eur J Immunol. 1988 Sep;18(9):1453-61. doi: 10.1002/eji.1830180923. PMID: 2901968.

Gonchoroff NJ, Katzmann JA, Currie RM, Evans EL, Houck DW, Kline BC, Greipp PR, **Loken MR**. S-phase detection with an antibody to bromodeoxyuridine. Role of DNase pretreatment. J Immunol Methods. 1986 Oct 23;93(1):97-101. doi: 10.1016/0022-1759(86)90438-2. PMID: 3772110.

Stall AM, Quintáns J, **Loken MR**. T15 idiotype expression in the murine response to phosphorylcholine is actively regulated by genes linked to the Igh-C locus. J Immunol. 1986 Apr 1;136(7):2689-96. PMID: 3081651.

Watkins JR, McNicholas JM, **Loken MR**, Knight KL. Characterization of functionally distinct subpopulations of rabbit T lymphocytes. Immunology. 1984 Dec;53(4):659-67. PMID: 6238903; PMCID: PMC1454873.

Lorber MI, Wall KA, **Loken MR**, Fitch FW. Control of cloned alloreactive T lymphocyte proliferative responses. A possible role for cell-surface-bound alloantigen. Transplantation. 1984 Oct;38(4):361-70. doi: 10.1097/00007890-198410000-00010. PMID: 6238456.

Stall AM, **Loken MR**. Allotypic specificities of murine IgD and IgM recognized by monoclonal antibodies. J Immunol. 1984 Feb;132(2):787-95. PMID: 6690619.

Loken MR, Kubitschek HE. Constancy of cell buoyant density for cultured murine cells. J Cell Physiol. 1984 Jan;118(1):22-6. doi: 10.1002/jcp.1041180106. PMID: 6690449.

Lorber MI, Dawson PJ, **Loken MR**, Ely JM, Fieldsteel AH, Fitch FW. T-cell lineage of a Friend virus-induced lymphatic leukemia in athymic rats. J Natl Cancer Inst. 1983 Dec;71(6):1271-80. PMID: 6361350.

Loken MR, Dessner-De Jose DS, Van Zant G, Goldwasser E. Characterization of murine hemopoietic cells using rat anti-mouse monoclonal antibodies. Hybridoma. 1983;2(1):55-68. doi: 10.1089/hyb.1983.2.55. PMID: 6678795.

Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintáns J, **Loken MR**, Pierres M, Fitch FW. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol. 1983 Nov;131(5):2445-51. PMID: 6415170.

Tartof D, Curran JJ, Levitt D, **Loken MR**. The skin test antigen stimulated killer (STAK) cell mediating NK like CMC is OKM1 positive and OKT3 negative. Clin Exp Immunol. 1983 Nov;54(2):561-6. PMID: 6360439; PMCID: PMC1535880.

Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintáns J, **Loken MR**, Pierres M, Fitch FW. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol. 1983 Nov;131(5):2445-51. PMID: 6415170

Taupier MA, Kearney JF, Leibson PJ, **Loken MR**, Schreiber H. Nonrandom escape of tumor cells from immune lysis due to intracloal fluctuations in antigen expression. Cancer Res. 1983 Sep;43(9):4050-6. PMID: 6871846.

Lancki DW, Lorber MI, **Loken MR**, Fitch FW. A clone-specific monoclonal antibody that inhibits cytolysis of a cytolytic T cell clone. J Exp Med. 1983 Mar 1;157(3):921-35. doi: 10.1084/jem.157.3.921. PMID: 6187881; PMCID: PMC2186961.

Shapiro SJ, Leibson PJ, **Loken MR**, Schreiber H. Changes in susceptibility to cytotoxic antibody among tumor cells surviving exposure to chemotherapeutic agents. Cancer Res. 1982 Jul;42(7):2622-7. PMID: 7083155.

Lancki DW, Lorber MI, **Loken MR**, Fitch FW. A clone specific monoclonal antibody which inhibits T cell-mediated cytotoxicity. Adv Exp Med Biol. 1982;146:557-62. doi: 10.1007/978-1-4684-8959-0_34. PMID: 6808814.

Balch CM, **Loken MR**, Dougherty PA, Ades EW. Expression of a 16,000 molecular weight antigen on human suppressor T lymphocytes. Cell Immunol. 1981 Oct;64(1):84-92. doi: 10.1016/0008-8749(81)90460-3. PMID: 6457697.

McNicholas JM, Raffeld M, **Loken MR**, Reiter H, Knight KL. Monoclonal antibodies to rabbit lymphoid cells: preparation and characterization of a T-cell-specific antibody. Mol Immunol. 1981 Sep;18(9):815-22. doi: 10.1016/0161-5890(81)90003-1. PMID: 7040945

Dialynas DP, **Loken MR**, Glasebrook AL, Fitch FW. Lyt-2-/Lyt 3- variants of a cloned cytolytic T cell line lack an antigen receptor functional in cytotoxicity. J Exp Med. 1981 Mar 1;153(3):595-604. doi: 10.1084/jem.153.3.595. PMID: 6788878; PMCID: PMC2186095.

Sarmiento M, **Loken MR**, Fitch FW. Structural differences in cell surface T25 polypeptides from thymocytes and cloned T cells. Hybridoma. 1981;1(1):13-26. doi: 10.1089/hyb.1.1981.1.13. PMID: 6149189.

Quintáns J, **Loken MR**, Quan ZS, Dick RF, Regueiro B. Alteration of clonal profile. II. Studies on the capacity of BALB/c splenic B cells to perpetuate responsiveness to phosphorylcholine and T 15 idiotype dominance. Eur J Immunol. 1981 Mar;11(3):236-41. doi: 10.1002/eji.1830110313. PMID: 6972308.

Balch CM, Ades EW, **Loken MR**, Shore SL. Human "null" cells mediating antibody-dependent cellular cytotoxicity express T lymphocyte differentiation antigens. J Immunol. 1980 Apr;124(4):1845-51. PMID: 6767776.

Black SJ, Goding JW, Gutman GA, Herzenberg LA, **Loken MR**, Osborne BA, van der Loo W, Warner NL. Immunoglobulin isoantigens (allotypes) in the mouse : V. Characterization of IgM allotypes. Immunogenetics. 1978 Dec;7(1):213-30. doi: 10.1007/BF01844009. PMID: 21302076.

Leibson PJ, Schreiber H, **Loken MR**, Panem S, Rowley DA. Time-dependent resistance or susceptibility of tumor cells to cytotoxic antibody after exposure to a chemotherapeutic agent. Proc Natl Acad Sci U S A. 1978 Dec;75(12):6202-6. doi: 10.1073/pnas.75.12.6202. PMID: 216016; PMCID: PMC393147.

Black SJ, van der Loo W, **Loken MR**, Herzenberg LA. Expression of IgD by murine lymphocytes. Loss of surface IgD indicates maturation of memory B cells. J Exp Med. 1978 Apr 1;147(4):984-96. doi: 10.1084/jem.147.4.984. PMID: 306413; PMCID: PMC2184255.

Herzenberg LA, Herzenberg LA, Black SJ, **Loken MR**, Okumura K, van der Loo W, Osborne BA, Hewgill D, Goding JW, Gutman G, Warner NL. Surface markers and functional relationships of cells involved in murine B-lymphocyte differentiation. Cold Spring Harb Symp Quant Biol. 1977;41 Pt 1:33-45. doi: 10.1101/sqb.1977.041.01.007. PMID: 408094.

Warner NL, Goding JW, Gutman GA, Warr GW, Herzenberg LA, Osborne BA, van der Loo W, Black SJ, **Loken MR**. Allotypes of mouse IgM immunoglobulin. Nature. 1977 Feb 3;265(5593):447-9. doi: 10.1038/265447a0. PMID: 401952.

Loken MR, Hayes JW, Gohlke JR, Brand L. Excited-state proton transfer as a biological probe. Determination of rate constants by means of nanosecond fluorometry. Biochemistry. 1972 Dec 5;11(25):4779-86. doi: 10.1021/bi00775a022. PMID: 4676272.

Kubitschek HE, Bendigkeit HE, **Loken MR**. Onset of DNA synthesis during the cell cycle in chemostat cultures. Proc Natl Acad Sci U S A. 1967 Jun;57(6):1611-7. doi: 10.1073/pnas.57.6.1611. PMID: 5340631; PMCID: PMC224520.

Dawson RB Jr, **Loken MR**, Crater DH. Hemoglobin functions in stored blood. IX. Preservative with pH to maintain red blood cell 2,3-DPG (function) and ATP (viability). Transfusion. 1972 Jan-Feb;12(1):46-52. PMID: 50